Page last updated: 2024-08-24

simendan and Cardiac Failure

simendan has been researched along with Cardiac Failure in 459 studies

Research

Studies (459)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (1.53)	18.2507
2000's	208 (45.32)	29.6817
2010's	186 (40.52)	24.3611
2020's	58 (12.64)	2.80

Authors

Authors	Studies
Jun, M; Lan, L; Libiya, Z; Shubin, J; Xiangli, S	1
Bartuś, S; Gąsior, M; Gierlotka, M; Grześk, G; Główczyńska, R; Jaguszewski, M; Kasprzak, JD; Kubica, J; Legutko, J; Leszek, P; Nessler, J; Pacileo, G; Ponikowski, P; Sobkowicz, B; Stępińska, J; Straburzyńska-Migaj, E; Tycińska, A; Wojakowski, W; Zawiślak, B; Zymliński, R	1
Errigo, V; Martucci, ML; Masarone, D; Melillo, E; Pacileo, G; Pacileo, R; Petraio, A; Pollesello, P	1
Aldea Perona, A; de Mora Martin, M; García-González, MJ; Jiménez Sosa, A; Lara Padron, A; López Díaz, J; López Fernandez, S; Martínez-Sellés, M; Morales Rull, JL; Ortiz Oficialdegui, P	1
Bergin, P; Cieslik, L; Dagan, M; Hare, JL; Kaye, DM; Lankaputhra, M; Leet, A; Patel, HC; Taylor, AJ; Warner, V; Yeung, T	1
Banai, S; Frydman, S; Granot, Y; Havakuk, O; Hochstadt, A; Ketchker, L; Korotetski, L; Laufer-Perl, M; Milwidsky, A; Sadeh, B; Sapir, O; Topilsky, Y	1
Li, M; Li, Y; Qu, T; Wan, Q; Yuan, F; Zhang, Y	1
Cheng, Z; Cui, X; Dong, X; Han, Y; Hong, Y; Huang, X; Li, Y; Mu, Y; Wang, Z; Zhang, L	1
Freimark, D; Grupper, A; Itelman, E; Kassif, Y; Kogan, A; Lavee, J; Lotan, D; Morgan, A; Segev, A; Shemesh, Y	1
Araszkiewicz, A; Grygier, J; Jankiewicz, S; Lesiak, M; Mularek-Kubzdela, T; Sławek-Szmyt, S	1
Biasucci, LM; Conte, C; Cribari, F; D'Aiello, A; Liuzzo, G; Narducci, ML; Pedicino, D; Ruggio, A	1
Banach, J; Dobosiewicz, M; Gilewski, W; Grześk, G; Hertmanowski, W; Kowalkowska, M; Rogowicz, D; Wołowiec, Ł	1
Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F	1
Afzal, O; Ahsan, MJ; Akhtar, MS; Alavudeen, SS; Altamimi, ASA; Hassan, MQ; Khurana, M; Rahman, SO; Sharma, AK; Siddiqui, A; Tabassum, F	1
Hyllen, S; Lindstedt, S	1
Carvalho, T; Correia, C; Cruz Ferreira, R; Ferreira Reis, J; Ilhão Moreira, R; Pereira da Silva, T; Pombo, D; Santos, C; Timóteo, AT; Valentim Gonçalves, A	1
Abecia, A; Castrodeza, J; Cobo-Marcos, M; Codina, P; de Frutos, F; de Juan-Baguda, J; Diez-Lopez, C; Dobarro, D; Donoso-Trenado, V; Escolar, V; Garcia-Pinilla, JM; Gómez-Otero, I; González-Babarro, E; Gonzalez-Costello, J; Lopez-Fernandez, S; Marzoa-Rivas, R; Melendo-Viu, M; Méndez-Fernández, AB; Moliner-Abós, C; Pastor, F; Rodriguez, M; Ruiz-Bustillo, S; Sagasti-Aboitiz, I; Solé-González, E; Tobar, J; Vaqueriza-Cubillo, D	1
Borbély, A; Csanádi, Z; Édes, I; Horváth, B; Nánási, PP; Papp, Z; Ráduly, AP; Sárkány, F; Szentandrássy, N; Tóth, A	1
Gruchała, M; Książczyk, M; Lelonek, M; Stopczyńska, I	1
Aydın, C; Kaplangoray, M	1
Abdelshafy, M; Berchtold-Herz, M; Caliskan, K; de By, TMMH; Elkoumy, A; Elsherbini, H; Elzomor, H; Gollmann-Tepeköylü, C; Gummert, J; Kimman, JR; Loforte, A; Meyns, B; Mohacsi, P; Paluszkiewicz, L; Reineke, D; Schoenrath, F; Simpkin, AJ; Soliman, O	1
Amani-Beni, R; GhasempourDabaghi, G; RabieeRad, M; Zare, MM	1
Lin, X; Liu, G	1
Li, D; Li, J; Zhang, L; Zhou, S	1
Dong, N; Guo, Q; Lan, H; Li, C; Shi, J; Wang, G; Xiong, T; Zhang, J; Zheng, Q	1
Capolupo, I; Columbo, C; De Rose, DU; Di Chiara, L; Dotta, A; Gandolfo, C; Giliberti, P; Landolfo, F; Martini, L; Pugnaloni, F; Ronchetti, MP; Santisi, A; Toscano, A	1
Bayes-Genis, A; Codina, P; De Frutos, F; de Juan-Bagudá, J; Dobarro, D; Gonzalez-Costello, J; Lupón, J	1
Amour, J; Cholley, B; Fellahi, JL; Levy, B; Longrois, D; Mebazaa, A; Ouattara, A	1
Caliskan, K; Yalcin, YC	1
Buttà, C; Miceli, G; Petrantoni, R; Pinto, A; Roberto, M; Tuttolomondo, A; Zappia, L	1
Campo Sien, C; Comín-Colet, J; Delgado Jimenez, JF; Díez López, C; Enjuanes Grau, C; González Costello, J; Manito Lorite, N; Rubio-Rodríguez, D; Rubio-Terrés, C; Segovia-Cubero, J	1
Di Chiara, L; Di Molfetta, A; Haiberger, R; Iacobelli, R; Marinari, E; Ricci, Z; Toscano, A	1
Bugajski, J; Duszańska, A; Feusette, P; Gierlotka, M; Płonka, J	1
Affronti, A; Bellani, G; Feri, M; Guarracino, F; Marini, M; Quacquarelli, A; Sangalli, F; Vitale, D; Volpi, F	1
Arribas Ynsaurriaga, F; de Juan Bagudá, JS; Delgado Jiménez, JF; García-Cosío Carmena, MD; Ponz de Antonio, I; Rodríguez Chaverri, A	1
Dobarro, D; Ribera-Solé, A	1
Dabrowski, W; Jaroszynski, A; Piasek, E; Schlegel, TT; Siwicka-Gieroba, D	1
Araújo, I; Campos, L; Cunha, GJL; Fernandes, L; Ferraz, M; Fonseca, C; Gomes, RV; Morais, R; Rocha, BML	1
Chen, Y; Cui, D; Li, G; Liao, Y	1
Mamalyga, LM; Mamalyga, ML	1
Aimo, A; Arzilli, C; Emdin, M; Rapezzi, C; Vergaro, G	1
Agostoni, P; Alvarez, J; Bettex, D; Bouchez, S; Brito, D; Černý, V; Comin-Colet, J; Crespo-Leiro, MG; Delgado, JF; Édes, I; Eremenko, AA; Farmakis, D; Fedele, F; Fonseca, C; Fruhwald, S; Girardis, M; Guarracino, F; Harjola, VP; Heringlake, M; Herpain, A; Heunks, LMA; Husebye, T; Ivancan, V; Karason, K; Kaul, S; Kivikko, M; Kubica, J; Lewinski, DV; Masip, J; Matskeplishvili, S; Mebazaa, A; Nieminen, MS; Oliva, F; Papp, JG; Papp, Z; Parissis, J; Parkhomenko, A; Põder, P; Pollesello, P; Pölzl, G; Reinecke, A; Ricksten, SE; Riha, H; Rudiger, A; Sarapohja, T; Schwinger, RHG; Toller, W; Tritapepe, L; Tschöpe, C; Vrtovec, B; Wikström, G	1
Bugajski, J; Deja, M; Depukat, R; Gierlotka, M; Gruchała, M; Grześk, G; Kasprzak, JD; Kubica, J; Kucewicz-Czech, E; Leszek, P; Płonka, J; Sobkowicz, B; Stępińska, J; Straburzyńska-Migaj, E; Tycińska, A; Wilk, K; Zawiślak, B; Zymliński, R	1
Bottio, T; Gerosa, G; Piperata, A	1
Amarelli, C; Cacciatore, F; Golino, P; Maiello, C; Palmieri, V	1
Masarone, D; Pacileo, G	1
Fu, M; Liu, Y; Wang, Z	1
Bachorzewska-Gajewska, H; Chlabicz, M; Dobrzycki, S; Kuźma, Ł; Zalewska-Adamiec, M	1
Beitzke, D; Gremmel, F; Hülsmann, M; Kammerlander, A; Laggner, R; Loewe, C; Nolz, R; Senn, D; Wielandner, A	1
Gruchała, M; Korościk, E; Lelonek, M; Stopczyńska, I; Straburzyńska-Migaj, E	1
Alvarez, J; Bettex, D; Bouchez, S; Fruhwald, S; Girardis, M; Grossini, E; Guarracino, F; Heringlake, M; Herpain, A; Pollesello, P; Toller, W; Tritapepe, L	1
Borlaug, BA; Burkhoff, D; Chung, ES; Lewis, GD; Majure, DT; Mazurek, JA; Preston, IR; Raza, F; Rich, JD; Rich, S; Shah, SJ; Simon, MA; Tedford, RJ; Thenappan, T; Zamanian, RT; Zolty, R	1
Filipiak, KJ; Gasecka, A; Jaguszewski, MJ; Szarpak, L; Targonski, R	1
Cui, DY; Hu, S; Hu, Y; Kuang, X; Liu, ZZ; Long, YX	1
Luo, B; Wang, M	1
Borlaug, BA; Brener, MI; Burkhoff, D; Hamid, NB; Rich, S; Shah, SJ; Sunagawa, K	1
Häberle, HA	1
Astuto, M; La Via, L; Merola, F; Sanfilippo, F	1
Conti, N; Diemberger, I; Gatti, M; Potena, L; Raschi, E	1
Altenberger, J; Baholli, L; Beltrán, P; Borbély, A; Bover, R; Comin-Colet, J; Delgado, JF; Fedele, F; Fontana, A; Fruhwald, F; Garcia-González, MJ; Giamouzis, G; Giannakoulas, G; Gustafsson, F; Kaikkonen, K; Kivikko, M; Kubica, J; Löfman, I; Malfatto, G; Manito, N; Martínez-Sellés, M; Masip, J; Merkely, B; Morandi, F; Mølgaard, H; Oliva, F; Pantev, E; Papp, Z; Perna, GP; Pfister, R; Piazza, V; Pollesello, P; Pölzl, G; Rangel-Sousa, D; Recio-Mayoral, A; Reinecke, A; Rieth, A; Sarapohja, T; Schmidt, G; Seidel, M; Störk, S; von Lewinski, D; Vrtovec, B; Wikström, G; Yerly, P	1
Shang, G; Shang, Y; Song, D; Tang, M; Ti, Y; Wang, Z; Yang, X; Zhang, W; Zhang, Y; Zhong, M	1
Andersen, A; Bogaard, HJ; Hansen, MS; Happé, C; Holmboe, S; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Simonsen, U	1
López, J; Rodríguez-Santamarta, M; Sayago, I	1
De Carlo, M; Fiorelli, F; Giannini, C; Guarracino, F; Liga, R; Marraccini, E; Petronio, AS; Pieroni, A; Spontoni, P	1
Hao, Y; Huang, S; Jia, L; Li, X; Ma, Y; Mao, Y; Qiu, J; Wang, M	1
Altenberger, J; Gustafsson, F; Harjola, VP; Karason, K; Kindgen-Milles, D; Kivikko, M; Malfatto, G; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C	1
Almeida, I; Caetano, F; Costa, M; Fernandes, A; Gonçalves, L; Madeira, M; Reis, L	1
Belletti, A; Fontana, A; Pollesello, P; Silvetti, S	1
Gong, SG; He, J; Jiang, R; Liu, JM; Luo, CJ; Qiu, HL; Wang, L; Wu, WH; Yuan, P; Zhang, R; Zhao, QH	1
Abbate, A; Van Tassell, BW	1
Brossier, D; Goyer, I; Toledano, B	1
Muehlschlegel, JD; Varelmann, DJ	1
Almenar, L; Blasco, T; Bruguera, J; Comín-Colet, J; Crespo-Leiro, MG; Delgado, J; García Pinilla, JM; Gonzalez-Vilchez, F; Grau, M; Lambert-Rodríguez, JL; Manito, N; Pascual-Figal, D; Segovia-Cubero, J; Sionis, A	1
Hage, C; Haugen Löfman, I; Lund, LH; Manouras, A; Najjar, E; Ottenblad, E; Stålhberg, M	1
Li, J; Zhang, L; Zhou, S	1
Altenberger, J; Pölzl, G	1
Chen, D; Matter, A; Sivakumar, N; Teneggi, V	1
Bettex, D; Jacky, A; Krüger, B; Paal, S; Rudiger, A; Seifert, B; Spahn, DR; Wilhelm, MJ	1
Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA	1
Grebenshchikov, OA; Lar'kov, RN; Likhvantsev, VV; Marchenko, DN; Ovezov, AM; Philippovskaya, ZS; Skripkin, YV; Sungurov, VA; Timoshin, SS; Ubasev, YV; Zabelina, TS	1
Anker, SD; Balligand, JL; Bauersachs, J; Brutsaert, D; Carrier, L; Chlopicki, S; Cleland, JG; de Boer, RA; de Keulenaer, G; Dietl, A; Eschenhagen, T; Fischmeister, R; Hamdani, N; Harjola, VP; Heinzel, FR; Heymans, S; Hilfiker-Kleiner, D; Holzmeister, J; Limongelli, G; Linke, WA; Lund, LH; Lyon, AR; Maack, C; Manstein, DJ; Masip, J; Mebazaa, A; Metra, M; Metzger, J; Mueller, C; Papp, Z; Pieske, B; Ponikowski, P; Ristić, A; Ruschitzka, F; Seferović, PM; Skouri, H; Tocchetti, CG; Yilmaz, MB; Zimmermann, WH	1
Andersson, B; Bartfay, SE; Bergh, N; Bollano, E; Dahlberg, P; Gilljam, T; Hjalmarsson, C; Karason, K; Lannemyr, L; Ljungman, C; Ricksten, SE; Rundqvist, B	1
Allipour Birgani, S; Altenberger, J; Comín-Colet, J; Delgado, JF; Fedele, F; García-Gonzáles, MJ; Gustafsson, F; Masip, J; Papp, Z; Pölzl, G; Störk, S; Ulmer, H; Vrtovec, B; Wikström, G	1
Bouchez, S; Fedele, F; Giannakoulas, G; Gustafsson, F; Harjola, VP; Karason, K; Kivikko, M; Oliva, F; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C; von Lewinski, D	1
Iotti, GA; Mojoli, F; Tavazzi, G; Via, G	1
Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D	1
Almeida, GR; Bernardo, WM; Buzzini, RF; Floriano, I; Silvinato, A	1
Li, J; Li, Y; Wang, XY; Yang, F; Yang, J; Yang, ZY; Yuan, P	1
Akin, Y; Aygun, E; Beyazal, OF; Demirkan, B; Karahan, M; Kervan, U; Kocabeyoglu, SS; Pac, M; Sert, DE; Unal, EU	1
Cameli, M; Incampo, E; Lunghetti, S; Mandoli, GE; Mondillo, S; Navarri, R; Palmerini, E; Righini, FM; Sciaccaluga, C; Sisti, N	1
Hou, ZQ; Hu, B; Shang, DY; Su, CY; Sun, ZX; Tan, H; Zhong, X; Zhou, Y	1
Kivikko, M; Kurttila, M; Laitinen, T; Magga, J; Miettinen, K; Parviainen, I; Peuhkurinen, K; Punnonen, K; Timonen, K; Timonen, P; Tuomainen, PO; Uusaro, A; Vanninen, E; Vuolteenaho, O	1
Banasiak, W; Biegus, J; Jankowska, EA; Kulej, K; Ponikowski, P; Szachniewicz, J; Zymliński, R	1
Cully, M	1
Huang, LQ; Huang, X; Jiang, RL; Lei, S; Xia, GL; Zhi, YH; Zhu, MF	1
Dipchand, AI; Mohseni-Bod, H; Tosoni, A	1
Bagalas, V; Boutou, AK; Paspala, A; Pitsiou, G; Stanopoulos, I	1
Angadi, U; Chowdhry, MF; Westrope, C	1
Elisha, N; Paret, G; Rubinsthein, M; Salem, I	1
Aldea-Perona, A; Cordero, M; de Mora-Martín, M; del Mar García-Saiz, M; García-González, MJ; Lara-Padrón, A; López-Díaz, J; López-Fernández, S; Marrero-Rodríguez, F; Martínez-Sellés, M; Romero-García, J	1
Barrett, NA; Berry, WT; Hewson, RW; Langrish, CJ; McKenzie, CA	1
Ata, Y; Eris, C; Turk, T; Yavuz, S	1
Hajj-Chahine, J	1
Desimonas, NA	1
Andersson, KB; Christensen, G; Golz, S; Hillestad, V; Knorr, A; Kramer, F	1
Franz, WM; Grabmaier, U; Hagl, C; Kaczmarek, I; Kreissl, N; Sodian, R; Steinbeck, G; Theiss, HD	1
Alibaz-Oner, F; Erguney, M; Gurbuz, OZ; Oner, E; Yurdakul, S	1
Bacaksiz, A; Erdogan, E; Ergelen, M; Erturk, M; Karakurt, H; Sonmez, O; Tasal, A; Turfan, M; Uyarel, H; Vatankulu, MA	1
de Lurdes, CM; Di Prima, AL; Greco, T; Landoni, G; Mucchetti, M; Pasin, L; Scandroglio, M; Silvetti, S; Zangrillo, A	1
Pollesello, P	1
Høydal, MA; Kolseth, SM; Nordhaug, DO; Rolim, NP; Salvesen, Ø; Wahba, A	1
Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T	1
Acarturk, E; Bacaksiz, A; Bozkurt, A; Demir, M; Eker, RA; Kanadasi, M; Sahin, DY; Tasal, A; Vatankulu, MA	1
Califf, RM	1
Colucci, W; Delgado-Herrera, L; Fisher, L; Garratt, C; Huang, B; Massie, BM; Packer, M; Padley, RJ; Salon, J; Sarapohja, T; Teerlink, JR; Thakkar, R; Young, J	1
O'Connor, C	2
Yeo, PSD	1
Barisin, A; Barisin, S; Djuzel, V; Rudez, I	1
Blengino, S; Branzi, G; Della Rosa, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Rella, V; Villani, A	1
Firlinger, F; Gegenhuber, A; Lenz, K; Lohr, G; Piringer, P	1
Guo, M; Jia, Z; Liang, HQ; Song, Y; Zhang, LY; Zhang, YQ	2
Cruz Mañas, J; Galán Ortega, M; Guerrero Orriach, JL; Iglesias, P; Navarro Arce, I; Rubio Navarro, M	1
Altenberger, J; Ben-Gal, T; Böhmer, A; Comin-Colet, J; Dickstein, K; Edes, I; Fedele, F; Fonseca, C; García-González, MJ; Giannakoulas, G; Iakobishvili, Z; Jääskeläinen, P; Karavidas, A; Kettner, J; Kivikko, M; Lund, LH; Matskeplishvili, ST; Metra, M; Morandi, F; Nieminen, MS; Oliva, F; Parissis, J; Parkhomenko, A; Pollesello, P; Pölzl, G; Schwinger, RH; Segovia, J; Seidel, M; Vrtovec, B; Wikström, G	1
Benson, L; Dahlström, U; Edner, M; Hagerman, I; Lund, LH; Thorvaldsen, T	1
Akturk, IF; Birant, A; Erturk, M; Karakurt, H; Kurtar Mansıroglu, A; Oner, E; Somuncu, MU; Uzun, F; Yalcin, AA; Yildirim, A	1
Altenberger, J; Avgeropoulou, E; Costard-Jaeckle, A; Dimopoulos, L; Ebner, C; Karavidas, A; Parissis, JT; Poelzl, G; Sihorsch, K; Ulmer, H; Weber, T; Winter, A	1
Chivite, D; Corbella, X; Formiga, F	1
Haddad, F; Hrovat, E; Knezevic, I; Oman, A; Pintar, T; Poglajen, G; Vrtovec, B; Wu, JC	1
De Luca, L	1
Makris, D; Papanikolaou, J; Tsolaki, V; Zakynthinos, E	1
Cismowski, MJ; de Tombe, P; Guggilam, A; Lucchesi, PA; Sadayappan, S; Trask, AJ; West, TA; Wilson, K; Zhang, X	1
Aliabadi, A; Buchberger, E; de Martin, R; Demyanets, S; Gröger, M; Hofer-Warbinek, R; Huber, K; Kastl, SP; Kaun, C; Krychtiuk, KA; Maurer, G; Pisoni, J; Rauscher, S; Speidl, WS; Watzke, L; Wojta, J; Zuckermann, A	1
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Seljeflot, I	1
Henriques-Coelho, T; Leite-Moreira, AF; Lourenço, AP; Moreno, N; Oliveira-Pinto, J; Tavares-Silva, M	1
Martín Herranz, MI; Martínez Roca, C; Vilaboa Pedrosa, C; Yáñez Gómez, P	1
Bistola, V; Farmakis, D; Filippatos, G; Frogoudaki, A; Ikonomidis, I; Kremastinos, D; Lekakis, J; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P; Vasiliadis, K	1
Favilli, R; Lunghetti, S; Mondillo, S; Palmerini, E; Söderberg, S	1
Li, JX; Niu, LL; Yi, GY; Zhang, CY; Zhang, J	1
Adam, M; Baldus, S; Costard-Jäckle, A; Klinke, A; Knors, H; Meyer, S; Radunski, UK; Rudolph, TK; Rudolph, V; Spin, JM; Tsao, PS	1
Acea, AB; Ferrer Hita, JJ; García-González, MJ; Jiménez-Sosa, A; Jorge-Pérez, P; Lacalzada Almeida, JB	1
Freeman, LJ; Rafiq, I	1
Ben-Gal, T; Buerke, M; Comín-Colet, J; Fedele, F; Karavidas, A; Kivikko, M; Nieminen, MS; Parissis, J; Pollesello, P; Severino, P; Wikström, G	1
Gong, B; Li, Z; Yat Wong, PC	1
Huang, J; Qian, J; Yao, Y; Zhang, D	1
Çavuşoğlu, Y; Demirtaş, S; Gencer, E; Güneş, H; Kalaycı, S; Korkmaz, Ş; Mert, UK; Mutlu, F; Özdemir, S; Şaşmaz, H; Yılmaz, MB	1
Nieminen, MS; Silvetti, S	1
Ji, F; Wen, Y	1
Andersen, A; Andersen, S; Hillgaard, TK; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Vildbrad, MD	1
Irving, M; Pineda-Sanabria, SE; Robertson, IM; Sun, YB; Sykes, BD	1
Ertl, G; Pauschinger, M; von Scheidt, W	1
Kumar, A; Kushwah, S; Sahana, KS	1
Harjola, VP; Kivikko, M; Nieminen, MS; Pollesello, P; Sarapohja, T; Tarvasmäki, T	1
Huang, Q; Qin, X; Yang, H	1
Buerke, M; Cohen-Solál, A; Costa, S; Édes, I; Erlikh, A; Franco, F; Gibson, C; Gorjup, V; Guarracino, F; Gustafsson, F; Harjola, VP; Husebye, T; Karason, K; Katsytadze, I; Kaul, S; Kivikko, M; Marenzi, G; Masip, J; Matskeplishvili, S; Mebazaa, A; Møller, JE; Nessler, B; Nessler, J; Nieminen, MS; Ntalianis, A; Oliva, F; Pichler-Cetin, E; Põder, P; Pollesello, P; Recio-Mayoral, A; Rex, S; Rokyta, R; Strasser, RH; Zima, E	1
Mauriat, P; Séguéla, PE; Tafer, N; Thambo, JB	1
Alvarez, J; Brito, D; Farmakis, D; Fedele, F; Fonseca, C; Gal, TB; Gordon, AC; Gotsman, I; Grossini, E; Guarracino, F; Harjola, VP; Hellman, Y; Heunks, L; Ivancan, V; Karavidas, A; Kivikko, M; Lomivorotov, V; Longrois, D; Masip, J; Metra, M; Morelli, A; Nikolaou, M; Papp, Z; Parissis, J; Parkhomenko, A; Poelzl, G; Pollesello, P; Ravn, HB; Rex, S; Ricksten, SE; Riha, H; Schwinger, RHG; Vrtovec, B; Yilmaz, MB; Zielinska, M	1
Asif, M	1
Birant, A; Eksik, A; Erturk, M; Kalkan, AK; Karakurt, H; Mansiroglu, AK; Oner, E; Ozturk, D; Somuncu, MU	1
Fruhwald, F; Fruhwald, S; Pollesello, P	1
Andersen, GØ; Bjørnerheim, R; Eritsland, J; Husebye, T	1
Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Oldani, M; Ortis, B; Parati, G; Villani, A	1
Anastasiou-Nana, M; Dimopoulos, S; Gerovasili, V; Kaldara, E; Kourtidou, S; Nanas, J; Nanas, S; Pierrakos, C; Roussos, C; Sarafoglou, S; Venetsanakos, J	1
Kapralou, A; Katsaragakis, S; Markogiannakis, H; Theodorou, D; Toufektzian, L	1
Andreadou, I; Bistola, V; Filippatos, G; Kremastinos, DT; Paraskevaidis, I; Parissis, JT	1
Beck-da-Silva, L; Fuchs, FD	1
Osório, AP; Rosa, EM; Scopel, L	1
Harjola, VP; Lassus, J; Melin, J; Nieminen, MS; Peuhkurinen, K; Rossinen, J; Siirila-Waris, K	1
Frick, M; Grander, W; Jonetzko, P; Metzler, B; Pachinger, O; Poelzl, G; Roithinger, FX; Ulmer, H; Zwick, RH	1
Akyuz, S; Alioglu, E; Bozkaya, YT; Duygu, H; Gunduz, R; Kirilmaz, B; Ozdogan, O; Payzin, S; Turk, U; Turkoglu, C	1
Harjola, VP; Jurkko, R; Nieminen, MS; Oikarinen, L; Puttonen, J; Sarapohja, T; Sundberg, S; Toivonen, L	1
Bagshaw, SM; Bradford, C; Delaney, A; Lee, R; McCaffrey, J	2
Francis, GS; Unzek, S	1
Bistola, V; Filippatos, G; Ikonomidis, I; Kremastinos, DT; Papadopoulos, C; Paraskevaidis, IA; Parissis, JT	1
Belenkov, Y; Cleland, JG; Eha, J; Kivikko, M; Nieminen, MS; Põder, P; Sarapohja, T	1
Bistola, V; Farmakis, D; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Paraskevaidis, IA; Parissis, JT	1
Endoh, M	3
Altinay, L; Cicekcioglu, F; Katircioglu, SF; Parlar, AI; Yay, K	1
Akilli, A; Akin, M; Duygu, H; Ergene, O; Erturk, U; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M	1
Economides, C; Kota, B; Prasad, AS; Singh, BN	1
Mebazaa, A; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P	1
Kass, DA	1
Tagarakis, GI; Tsilimingas, NB	1
Cleland, JG; Cohen-Solal, A; Filippatos, GS; Huang, B; Mebazaa, A; Nieminen, MS; Padley, RJ; Salon, JE; Thakkar, R	1
Erdem, A; Karadas, F; Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB; Yontar, C	2
Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C	1
Carrio, ML; Farrero, E; Miralles, A; Rodriguez-Castro, D; Ruiz-Majoral, A; Torrado, H; Ventura, JL	1
Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Stefanadi, E; Stefanadis, C; Tousoulis, D	1
Beyan, C; Ifran, A; Kaptan, K	1
Beiras-Fernandez, A; Kaczmarek, I; Kur, F; Reichart, B; Schmoeckel, M; Sodian, R; Weis, F; Weis, M	1
Abreu-Lima, C; Amorim, S; Damasceno, A; Ferreira, J; Ferreira, R; Fonseca, C; Ilídio-Moreira, J; Lousada, N; Martins-de-Campos, J; Oliveira-Soares, A; Rabaçal, C; Seabra-Gomes, R; Silva-Cardoso, J	1
Chay Woodward, T; de Lissovoy, G; Fraeman, K; Salon, J; Sterz, R	1
Cai, D; Cohen-Solal, A; Huang, B; Logeart, D; Mebazaa, A; Nieminen, MS	1
de Lissovoy, G; Durtschi, A; Fraeman, K; Mullahy, J; Padley, RJ; Salon, J; Sterz, R; Teerlink, JR	1
Kirkeby-Garstad, I; Kolseth, SM; Nordhaug, DO; Sellevold, O; Stenseth, R; Wahba, A	1
Jaykumar, I; Kamath, SR; Matha, S	1
Finckenberg, P; Forsten, H; Kaheinen, P; Kytö, V; Leskinen, H; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Tikkanen, I; Vahtola, E	1
Ambrosio, G; De Maria, R; Di Lenarda, A; Fedele, F; Gabrielli, D; Metra, M; Oliva, F; Perna, G; Senni, M	1
Kiviniemi, V; Kurola, J; Leppikangas, H; Lindgren, L; Ruokonen, E; Rutanen, J	1
Filippatos, G; Parissis, JT	1
Kytö, V; Latva-Hirvelä, J; Levijoki, J; Saraste, A; Saukko, P; Vuorinen, T	1
Ertmer, C; Morelli, A; Pietropaoli, P; Westphal, M	1
Bilgehan, K; Duman, D; Palit, F; Sacide, A; Simsek, E	1
Cao, DX; Cao, MH; He, B; He, WX; Li, J; Peng, SL; Xia, SX; Xu, ZD; Yang, T; Zhao, YF	1
Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V	1
Despas, F; Franchitto, N; Galinier, M; Labrunee, M; Pathak, A; Senard, JM; Trouillet, C	1
Grande, DB; Hidalgo, RL; Morales, SC; Moyano, AP	1
Altenberger, J; Parissis, JT; Poelzl, G; Ulmer, H	1
Liaudet, L; Rusca, M	1
Omerovic, E; Swedberg, K; Waagstein, F	1
Andersson, B; Bergh, CH; Dahlström, U; Forfang, K; Kivikko, M; Sarapohja, T; Ullman, B; Wikström, G	1
Duman, D; Fotbolcu, H	1
Dexeus, D; Hoffman, RS; Lugassy, DM; Nelson, LS; Stefan, A	1
Alexander, PM; Butt, WW; Penny, DJ; Ryerson, LM; Shann, FA; Shekerdemian, LS	1
Busani, S; Cobelli, M; Girardis, M; Pasetto, A; Rinaldi, L; Severino, C	1
Ata, N; Beyaztas, A; Birdane, A; Cavusoglu, Y	1
Polanczyk, CA; Ribeiro, RA; Rohde, LE	1
Arutiunov, AG; Arutiunov, GP; Volkova, AL	1
Branzi, G; Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Revera, M; Rosa, FD; Villani, A	1
Campia, U; Gheorghiade, M; Nodari, S	1
Banach, M; Kowalczyk, M; Kozłowski, D; Lip, GY; Mikhailidis, DP; Rysz, J	1
Buerke, M; Lemm, H; Russ, M; Schlitt, A; Werdan, K	1
Wikström, BG	1
Ayub-Ferreira, SM; Bacal, F; Bocchi, EA; Mangini, S; Marcondes-Braga, FG	1
Batur, MK; Kurt, IH; Yavuzer, K	1
Tandoğan, I; Yalta, K; Yilmaz, MB; Yontar, OC	1
Biala, A; Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Luft, FC; Martonen, E; Merasto, S; Mervaala, E; Muller, DN	1
Andrade Acuña, G; Dekhuijzen, PN; Heunks, LM; Linkels, M; van Hees, HW	1
Alsina, E; Brogly, N; Gilsanz, F; Guasch, E; López, T; Puertas, L	1
Buerke, U; Buerkem, B; Dietz, S; Krohe, K; Lemm, H; Raaz, U; Russ, M; Schlitt, A; Werdan, K	1
Cui, L; Hao, YM; Jiang, DJ; Li, GP; Li, HM; Liu, J; Qi, GX; Wang, L; Wang, WZ; Wei, JP; Zhang, YD	1
Apostolakis, S; Lazaridis, K; Spandidos, DA; Tzoras, S; Zaravinos, A	1
Fox, CJ; Kaye, AD; Liu, H; Zhang, S	1
Fields, AM; Milligan, DJ	1
Erdem, A; Tandogan, I; Yalta, K; Yilmaz, MB; Yontar, OC	1
Colucci, WS; Karlsson, MO; Kivikko, M; Pohjanjousi, P; Sundberg, S	1
Anastasiou-Nana, M; Bistola, V; Ikonomidis, I; Papadopoulos, C; Paraskevaidis, IA; Parissis, J; Stassinos, V	1
Ata, N; Birdane, A; Cavuşoğlu, Y; Demirüstü, C; Göktekin, Ö; Görenek, B; Tek, M; Ünalır, A	1
Bongo, AS; Lazzero, M; Lupi, A; Rognoni, A; Rognoni, G	1
Auteri, A; Di Renzo, M; Maffei, S; Pasqui, AL; Pompella, G; Puccetti, L	1
Böhm, M; Cai, D; Cohen Solal, A; Filippatos, GS; Huang, B; Kivikko, M; Link, A; Mebazaa, A; Nieminen, MS; Padley, RJ; Salem, R	1
Bautista-Hernandez, V; Fynn-Thompson, F; Portela, F; Sanchez-Andres, A	1
Harjola, VP; Jalanko, M; Kivikko, M; Laine, M; Nieminen, MS	1
Feola, M; Lombardo, E; Piccolo, S; Taglieri, C; Vallauri, P; Valle, R	1
Hoffman, TM	1
Bettari, L; Bugatti, S; Carubelli, V; Danesi, R; Dei Cas, L; Lazzarini, V; Lombardi, C; Metra, M; Monti, A; Villa, C	1
Cheng, CP; Cheng, HJ; Little, WC; Masutani, S; Tachibana, H	1
Beggino, C; Caimmi, PP; Crosio, E; Giustini, G; Grossini, E; Kapetanakis, EI; Micalizzi, E; Molinari, C; Reposo, G; Vacca, G	1
Kiviniemi, V; Lahtinen, P; Pitkänen, O; Pölönen, P; Turpeinen, A; Uusaro, A	1
Brasolin, B; Bruno, N; Caira, C; D'Ambrosi, A; Fedele, F; Mancone, M	1
Kaheinen, P; Lakkisto, J; Lakkisto, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Storvik, M; Tikkanen, I; Vahtola, E	1
Kantor, PF; Timberlake, K	1
Gautreux Minaya, S; Lobo Martínez, P; Oulego Erroz, I; Rodríguez Fernández, LM	1
Bellmann, R; Bertocchi, C; Bijuklic, K; Dunzendorfer, S; Hasslacher, J; Joannidis, M; Kountchev, J	1
Dzhaiani, NA; Gnidkina, NA; Kositsyna, IV; Tereshchenko, SN	1
Bakır, F; Berker, D; Cetin, M; Çetin, ZG; Ciçekçioğlu, H; Güler, S; Işık, S; Ozuğuz, U; Uçar, O	1
Bocchi, EA; Carvalho, VO; Cruz, F; Guimarães, GV; Issa, VS; Moura, LZ	1
Mebazaa, A; Yilmaz, MB	1
Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E	1
Lehmann, A; Radke, J; Sack, FU	1
Favilli, R; Focardi, M; Guarino, E; Lunghetti, S; Maffei, S; Mondillo, S; Palmerini, E; Urselli, R	1
Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C	1
Bignami, E; Biondi-Zoccai, G; Greco, M; Greco, T; Guarracino, F; Landoni, G; Morelli, A; Zangrillo, A	1
Bersani, I; Conti, G; De Carolis, MP; De Rosa, G; Pardeo, M; Piastra, M; Romagnoli, C; Stival, E; Tempera, A	1
Allegaert, K; Thewissen, L	1
Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V	1
Borlu, F; Dal, MS; Oztekin, E; Paksoy, F; Tursun, I; Ulaş, T	1
Aro, S; Høydal, M; Kirkeby-Garstad, I; Kolseth, SM; Nordgaard, H; Nordhaug, D; Rognmo, Ø; Wahba, A	1
Gongadze, NV; Sukoyan, GV	1
An, T; Huang, Y; Lü, R; Qing, EM; Qing, P; Wei, BQ; Zhang, J; Zhang, YH; Zhou, Q; Zou, CH	1
Bai, XJ; Huang, Y; Jiang, YN; Li, H; Liu, WX; Qing, EM; Qu, P; Sun, YX; Wei, BQ; Zhang, J; Zhang, L; Zhang, YH; Zhou, Q	1
Barillà, F; Dominici, T; Giordano, F; Jacomelli, I; Pellicano, M	1
Amir, O; Zafrir, B	1
Arai, M	1
Büyüklü, M; Kürüm, AT; Set, T; Tatlý, E	1
Aydoğdu, S; Cetin, M; Cicekçioğlu, H; Güven Cetin, Z; Sahin, M; Uçar, O; Vasfi Ulusoy, F	1
Colucci, WS; Kivikko, M; Mebazaa, A; Nieminen, MS; Pohjanjousi, P; Pollesello, P; Teerlink, JR	1
Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A	1
Cohen, A; Hasin, Y; Nahir, M; Qarawani, D	1
Cai, D; Cohen-Solal, A; Deye, N; Kivikko, M; Laribi, S; Laterre, PF; Mebazaa, A; Nikolaou, M; Parissis, J; Paugam-Burtz, C; Poder, P; Pohjanjousi, P; Seronde, MF; Yilmaz, MB	1
Bacchini, S; Bongo, AS; Cavallino, C; Lupi, A; Rognoni, A; Rosso, R; Secco, GG; Veia, A	1
Apajasalo, M; D'Ambrosi, A; Fedele, F; Lucioni, C; Mazzi, S; Pollesello, P	1
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Müller, C; Sandvik, L; Seljeflot, I	1
Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M	1
Coats, AJ	1
Andrejevs, N; Golikov, AP; Kobalava, ZD; Laine, T; Lazebnik, LB; Lehtonen, LA; Lie, KI; Moiseyev, VS; Nieminen, MS; Põder, P; Ruda, MY	1
Antila, S; Eha, J; Kivikko, M; Lehtonen, L; Pentikäinen, PJ	2
Young, JB	1
Colucci, WS; Kivikko, M; Lehtonen, L	1
Borghi, C; Greenberg, B; Perrone, S	1
Apajasalo, M; Cleland, JG; Kobelt, G; Takala, A; Zethraeus, N	1
Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM	1
Teerlink, JR	2
Bouali, R; Dubois, MJ; Verdant, CL	1
Gronda, E; Mangiavacchi, M	1
Antila, S; Jonsson, EN; Karlsson, MO; Lehtonen, L; McFadyen, L	1
Erhardt, L; Mebazaa, A	1
Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Planken, U; Põder, P; Rantanen, S; Sundberg, S	2
Frishman, WH	1
Boldt, J; Kirchner, J; Lehmann, A	1
McBride, BF; White, CM	1
Erhardt, LR	1
Nieminen, MS; Sandell, EP	1
Follath, F	2
Anifantakis, A; Athanassopoulos, G; Chatzigeorgiou, G; Cokkinos, DV; Iakovis, P; Karatasakis, G; Koutsogiannis, N; Manginas, A; Maounis, T; Papadakis, M; Spargias, KS	1
Cavana, M; Fraticelli, A; Mebazaa, A; Pignataro, C	1
Innes, CA; Wagstaff, AJ	1
Krum, H; Liew, D	1
Borges, A; Braun, JP; Dohmen, P; Döpfmer, U; Kastrup, M; Kox, W; Roots, I; Schneider, M; Spies, C	1
Antila, S; Eha, J; Heikkilä, A; Kivikko, M; Lehtonen, L; Pentikäinen, PJ; Pohjanjousi, P	1
Delle Karth, G; Heinz, G	1
Cleland, JG; McGowan, J; Nikitin, N	1
Riggs, JM	1
Adamopoulos, S; Antoniades, C; Iliodromitis, E; Kostakis, G; Kremastinos, D; Kyrzopoulos, S; Parissis, JT; Rigas, A	1
Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P	1
Lehtonen, L; Lilleberg, J; Toivonen, L; Ylönen, V	1
Graham, CA	1
Kwok, BW	1
Baixas, C; Couderc, P; Delay, M; Galinier, M; Maury, P; Pathak, A; Roncalli, J	1
Eriksson, O; Haikala, H; Pollesello, P	1
Anker, SD; Diller, GP; von Haehling, S	1
Cheng, CP; Cheng, HJ; Igawa, A; Little, WC; Tachibana, H; Ukai, T; Zhang, ZS	1
Agrios, N; Anastasiou-Nana, MI; Christodoulou, K; Dalianis, A; Kanakakis, J; Nanas, JN; Papazoglou, PP; Terrovitis, JV; Tsagalou, EP; Tsolakis, E	1
Pollesello, P; Solaro, RJ; Sorsa, T	1
Abreu e Lima, C; Cardoso, JS; Damasceno, A; de Campos, JM; de Sá, EP; Ferreira, J; Ferreira, R; Fonseca, C; Lousada, N; Moreira, JI; Rabaçal, C; Seabra-Gomes, R	1
Kivikko, M; Lehtonen, L	1
Alexopoulos, GP; Anastasiou-Nana, MI; Kanakakis, J; Nanas, JN; Nanas, SN; Ntalianis, A; Papazoglou, P; Terrovitis, JV; Tsagalou, EP; Tsolakis, E	1
Adamopoulos, S; Degiannis, D; Iliodromitis, E; Kostakis, G; Kremastinos, DT; Kyrzopoulos, S; Parissis, JT; Rassias, J	1
Farmakis, D; Kremastinos, DT; Parissis, JT	2
Chatterjee, K; Foster, E; Gerber, IL; Jordan, MV; Kostal, M; McKeown, B; Michaels, AD; Vakharia, KT	1
Brixius, K; Schwinger, RH	1
Csapó, K; Edes, I; Haikala, H; Papp, Z; Pollesello, P	1
Andreadou, I; Androulakis, A; Avgeropoulou, C; Demopoulou, M; Kallikazaros, I; Markantonis-Kyroudis, S; Missovoulos, P	1
Gegenhuber, A; Haltmayer, M; Mueller, T	1
Paraskevaidis, IA; Parissis, JT; Th Kremastinos, D	1
Bonnefoy, E; Trindade, PT	1
Erhardt, L	1
Lehtonen, L	2
Barretto, AC; Canaviera, R; Follador, W; Martins, ML; Oliveira, MT; Scipioni, A; Tsuji, RL	1
Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, DT; Lekakis, J; Panou, F; Paraskevaidis, I; Parissis, JT; Venetsanou, K	1
Reingardiene, D	1
Berger, R; Bojic, A; Huelsmann, M; Moertl, D; Pacher, R	1
Kaplinsky, EJ; Perrone, SV	1
MacGowan, GA	2
Colucci, WS; Maytin, M	1
Gheorghiade, M; Mebazaa, A; Teerlink, JR	1
Barraud, D; Mebazaa, A; Welschbillig, S	1
Cardoso, JS; Follath, F; Franco, F	1
Earl, GL; Fitzpatrick, JT	1
Dernellis, J; Panaretou, M	1
Herzig, S; Hoppe, UC; Michels, G	1
Huang, SJ; McLean, AS; Nalos, M; Ting, I	1
Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, D; Paraskevaidis, I; Parissis, JT	1
Nanas, JN; Tsagalou, EP	1
Akhter, MW; Ng, TM	1
Rasmussen, T; Schmidt, H	1
Chalikias, GK; Hatseras, DI; Hatzinikolaou, HI; Kaski, JC; Kortsaris, AX; Maltezos, E; Papanas, N; Stakos, DA; Tentes, IK; Tziakas, DN	1
Brixius, K; Hoyer, HK; Schwinger, RH	1
Flaim, BD; MacIsaac, AI; Prior, DL; Yii, MY	1
McLachlan, CS; Mossop, P	1
Mehra, MR	1
Atar, D; Hodt, A; Steine, K	1
Böttiger, BW; Motsch, J; Rauch, H	1
Francis, D	1
Domínguez Rodríguez, A; García González, MJ	1
Colucci, WS; De Luca, L; Gheorghiade, M; Massie, BM; Nieminen, MS	1
Antoniades, C; Karamitros, I; Latsios, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Trikas, A; Vasiliadou, K	1
Adamopoulos, S; Farmakis, D; Filippatos, GS; Gheorghiade, M; Iliodromitis, EK; Karatzas, D; Kremastinos, DT; Paraskevaidis, I; Parissis, JT; Tsiapras, D	1
Hennersdorf, M; Müller, K; Peters, A; Strauer, BE; Zeus, T	1
Kivikko, M; Kupari, M; Laine, M; Lilleberg, J; Palkama, T; Pohjanjousi, P	1
Ahmadi, R; Berger, R; Bojic, A; Heissenberger, I; Huelsmann, M; Moertl, D; Pacher, R	1
Munger, MA	1
Brimioulle, S; Demester, JP; Fesler, P; Huez, S; Kerbaul, F; Naeije, R; Rondelet, B	1
Giannakoulas, G; Giannoglou, G; Kalpidis, P; Louridas, G; Martiadou, K; Parharidis, G; Vassilikos, V	1
Feres, GA; Garcia, JA; Hansen, MH; Holanda, GS; Salluh, JI; Simvoulidis, LF; Soares, M; Souza, RC; Toscano, L	1
Caimmi, PP; Grossini, E; Molinari, C; Teodori, G; Vacca, G	1
Adamopoulos, S; Farmakis, D; Filippatos, G; Iliodromitis, E; Kremastinos, DT; Panou, F; Paraskevaidis, I; Parissis, JT	1
Bistola, V; Farmakis, D; Filippatos, G; Kourea, K; Kremastinos, D; Nikolaou, M; Panou, F; Paraskevaidis, I; Parissis, JT	1
Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT	1
Lechner, E; Mair, R; Moosbauer, W; Pinter, M; Tulzer, G	1
Adamopoulos, S; Bistola, V; Farmakis, D; Kremastinos, DT; Parissis, JT	1
Agewall, S; Atar, D	1
Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M	1
Cam, N; Kasikcioglu, HA	1
Benezet-Mazuecos, J; de la Hera, J	1
Antoniades, C; Koumallos, N; Marinou, K; Stefanadis, C; Tousoulis, D	1
Lehtonen, L; Põder, P	1
Cavusoglu, Y	1
Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S	1
Erdem, A; Karadas, F; Tandogan, I; Yilmaz, MB	1
De Keulenaer, B; Powell, BP	1
Cohen-Solal, A; Kivikko, M; Kleber, FX; Mebazaa, A; Nieminen, MS; Packer, M; Padley, RJ; Pocock, SJ; Põder, P; Thakkar, R	1
Farmakis, D; Nieminen, M; Parissis, JT	1
Arapi, S; Bistola, V; Farmakis, D; Filippatos, G; Karavidas, A; Korres, D; Kremastinos, DT; Matsakas, E; Paraskevaidis, IA; Parissis, JT	1
Izumi, T; Shinagawa, H	1
Iwama, Y; Takagi, A	1
Kajimoto, K; Kawana, M; Watanabe, H	1
Yasumura, Y	1
Antila, S; Lehtonen, LA; Sundberg, S	1
Bistola, V; Farmakis, D; Filippatos, G; Kremastinos, D; Nikolaou, M; Papadopoulos, C; Paraskevaidis, I; Parissis, JT	1
Bunc, M; Vrtovec, B; Yazdanbakhsh, AP; Zemljic, G	1
Knez, I; Toller, W	1
Carbajosa-Dalmau, J; Carrasco-Moreno, R; Climent-Payá, V; Diéguez-Zaragoza, S; Fernández-Cañadas, J; Laghzaoui, F; Llorens-Soriano, P; Murcia-Zaragoza, J	1
Ma, J; Song, ZZ	1
Butler, J; Giamouzis, G; Giannakoulas, G	1
Andreadou, I; Bistola, V; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Louka, A; Markantonis, SL; Paraskevaidis, I; Parissis, JT; Pyriochou, A	1
Graudins, A; Najafi, J; Rur-SC, MP	1
Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Yildiz, A; Zoghi, M	1
Damman, K; Voors, AA	1
Simes, DC	1
Bistola, V; Filippatos, G; Ikonomidis, I; Kourea, K; Kremastinos, DT; Lekakis, J; Paraskevaidis, I; Parissis, JT	1
Tang, WH	1
Angus, JA; Royse, AG; Royse, CF; Soeding, PE; Wright, CE	1
Felker, GM; Petersen, JW	1
Khouadja, H; Mebazaa, A; Rezlan, E; Tavares, M; Vostroknoutova, I	1
Cheng, CP; Cheng, HJ; Heikkilä, A; Hyttilä-Hopponen, M; Levijoki, J; Little, WC; Masutani, S; Vuorela, A	1
Archan, S; Toller, W	1
Antoniades, C; Koumallos, N; Shirodaria, C; Stefanadis, C; Tousoulis, D	1
Best, M; Dembo, L; Driscoll, GO; Parle, NM; Thomas, MD	1
Birhan, M; Yilmaz, MB	1
Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F	1
Rabasseda, X	1
Albuquerque, D; Baima, J; Barretto, AC; Bocchi, EA; Lage, S; Moreira, Mda C; Rassi, S; Ribeiro, JP; Vilas-Boas, F	1
Andrade, AC; Mebazaa, A; Tavares, M	1
Ghazwinian, N; Hochmair, N; Mueller, T; Plöchl, W; Ponschab, M	1
Kapralou, A; Katsaragakis, S; Kofinas, G; Larentzakis, A; Markogiannakis, H; Menenakos, E; Theodoraki, EM; Theodorou, D	1
Ertmer, C; Pinto, BB; Rehberg, S; Westphal, M	1
Garrido Bravo, IP; Manzano-Fernández, S; Marín, F; Pascual Figal, DA	1
Agha, SA; Butler, J; Georgiopoulou, V; Giamouzis, G; Giannakoulas, G; Kalogeropoulos, A; Karvounis, H; Tsarpalis, K	1
Celik, T; Iyisoy, A; Kardesoglu, E; Yuksel, UC	1
Papp, JG; Udvary, E; Végh, A	1
Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Mesikepp, A; Planken, U; Sandell, EP	1
Antila, S; Hayha, M; Heikkinen, P; Lehtonen, LA; Ottoila, P; Pentikainen, PJ; Sandell, EP	1
Akkila, J; Lehtonen, L; Mills-Owens, P	1
Katz, SD; Mathew, L	1
Castell, M; Hasenfuss, G; Just, H; Kretschmann, B; Maier, LS; Pieske, B	1
Cleland, JG; Gomes, UC	1
Colucci, WS; Gottlieb, SS; Greenberg, BH; Haeusslein, E; Hare, J; Hutchins, S; Leier, CV; LeJemtel, TH; Loh, E; Nicklas, J; Ogilby, D; Singh, BN; Slawsky, MT; Smith, W	1
Akkila, J; Hasenfuss, G; Kleber, FX; Lehtonen, LA; Mitrovic, V; Nieminen, MS; Nyquist, O; Remme, WJ	1
Akkila, J; Iida, H; Karanko, M; Knuuti, J; Lehikoinen, P; Lehtonen, L; Någren, K; Saraste, M; Ukkonen, H; Voipio-Pulkki, LM	1
Orrù, P; Porcu, M	1
Lehtonen, LA	1
Figgitt, DP; Gillies, PS; Goa, KL	1
Brixius, K; Reicke, S; Schwinger, RH	1
Chin, BS; Lip, GY	1
Cleland, JG; McGowan, J	1
Laine, M; Lehtonen, L; Nieminen, MS	1

Reviews

138 review(s) available for simendan and Cardiac Failure

Article	Year
The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153 Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2022
Levosimendan: mechanistic insight and its diverse future aspects in cardiac care. Acta cardiologica, 2023, Volume: 78, Issue:2 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocytes, Cardiac; Pyridazines; Simendan; Stroke Volume	2023
Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review. Current problems in cardiology, 2023, Volume: 48, Issue:9 Topics: Cardiomyopathy, Hypertrophic; Heart Failure; Humans; Simendan; Stroke Volume	2023
Effect of Levosimendan on B-type Natriuretic Peptide Levels in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:7 Topics: Heart Failure; Humans; Natriuretic Peptide, Brain; Patients; Simendan	2023
The anti-inflammatory and haemodynamic effects of levosimendan on advanced heart failure patients: a meta-analysis of published studies. The Journal of international medical research, 2023, Volume: 51, Issue:7 Topics: Anti-Inflammatory Agents; Databases, Factual; Heart Failure; Hemodynamics; Humans; Interleukin-6; Simendan	2023
Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Critical care (London, England), 2019, Nov-29, Volume: 23, Issue:1 Topics: Cardiotonic Agents; Expert Testimony; Heart Failure; Humans; Perioperative Medicine; Randomized Controlled Trials as Topic; Simendan	2019
Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:1 Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Ventricular Function, Left	2021
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of cardiovascular pharmacology, 2020, Volume: 76, Issue:1 Topics: Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Patient Safety; Simendan; Treatment Outcome; Vasodilation; Vasodilator Agents	2020
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert review of cardiovascular therapy, 2021, Volume: 19, Issue:4 Topics: Adrenergic beta-Antagonists; Cardiac Surgical Procedures; Cardiotonic Agents; Critical Care; Dobutamine; Heart Failure; Hemodynamics; Humans; Shock, Cardiogenic; Simendan	2021
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiology journal, 2021, Volume: 28, Issue:3 Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome	2021
Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. Journal of cardiovascular pharmacology, 2021, 06-01, Volume: 77, Issue:6 Topics: Cardiotonic Agents; Diastole; Echocardiography; Heart Failure; Humans; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Systole; Ventricular Function, Left; Ventricular Function, Right	2021
[Levosimendan - a 20-Year Experience]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2021, Volume: 56, Issue:6 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2021
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug design, development and therapy, 2021, Volume: 15 Topics: Adenosine Triphosphate; Cardiotonic Agents; Heart Failure; Humans; Phosphodiesterase 3 Inhibitors; Simendan; Vasodilator Agents	2021
Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. International journal of cardiology, 2017, Sep-15, Volume: 243 Topics: Administration, Oral; Cardiotonic Agents; Clinical Trials as Topic; Consensus Development Conferences as Topic; Drug Administration Schedule; Europe; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Rome; Simendan	2017
Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan	2017
Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis. Life sciences, 2017, Sep-01, Volume: 184 Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; Vasodilator Agents	2017
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of cardiovascular pharmacology, 2018, Volume: 71, Issue:3 Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Clinical Decision-Making; Congresses as Topic; Databases, Factual; Heart Failure; Humans; Myocardial Contraction; Patient Selection; Recovery of Function; Risk Factors; Simendan; Treatment Outcome; Vasodilation; Vasodilator Agents	2018
Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC heart failure, 2017, Volume: 4, Issue:4 Topics: Cause of Death; Dose-Response Relationship, Drug; Drug Administration Schedule; Global Health; Heart Failure; Humans; Hydrazones; Patient Readmission; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Vasodilator Agents	2017
Noteworthy Literature published in 2017 for Cardiothoracic Anesthesiologists. Seminars in cardiothoracic and vascular anesthesia, 2018, Volume: 22, Issue:1 Topics: Adrenal Cortex Hormones; Anesthesiologists; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Methylprednisolone; Pyridazines; Simendan; Thrombelastography; Transcatheter Aortic Valve Replacement	2018
Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis. Herz, 2019, Volume: 44, Issue:7 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Prospective Studies; Pyridazines; Simendan	2019
Drugs' development in acute heart failure: what went wrong? Heart failure reviews, 2018, Volume: 23, Issue:5 Topics: Acute Disease; Cardiotonic Agents; Drug Approval; Drug Development; Heart Failure; Humans; Natriuretic Peptide, Brain; Simendan	2018
Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:6 Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Congresses as Topic; Evidence-Based Medicine; Heart Failure; Humans; Kidney; Myocardial Contraction; Recovery of Function; Simendan; Time Factors; Treatment Outcome; Vasodilator Agents	2018
Decompensated congestive heart failure - treatment with levosimendan. Revista da Associacao Medica Brasileira (1992), 2019, May-02, Volume: 65, Issue:4 Topics: Brazil; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Decision-Making; Heart Failure; Humans; Reproducibility of Results; Risk Factors; Simendan; Treatment Outcome	2019
Effects of levosimendan in heart failure: The role of echocardiography. Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:8 Topics: Cardiotonic Agents; Echocardiography; Heart Failure; Heart Ventricles; Humans; Simendan; Stroke Volume; Systole; Ventricular Function, Left	2019
Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Journal of Zhejiang University. Science. B, 2013, Volume: 14, Issue:5 Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Comorbidity; Critical Illness; Dobutamine; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Hypotension; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Survival Rate; Treatment Outcome	2013
The use of levosimendan in children with cancer with severe acute cardiac dysfunction: case series and a review of the literature. Cardiology in the young, 2014, Volume: 24, Issue:3 Topics: Acute Disease; Antineoplastic Agents; Cardiotonic Agents; Child, Preschool; Female; Heart Failure; Humans; Hydrazones; Leukemia, Myeloid, Acute; Neuroblastoma; Pyridazines; Severity of Illness Index; Simendan	2014
Is levosimendan effective in paediatric heart failure and post-cardiac surgeries? Interactive cardiovascular and thoracic surgery, 2013, Volume: 17, Issue:4 Topics: Age Factors; Benchmarking; Cardiac Surgical Procedures; Cardiovascular Agents; Child, Preschool; Evidence-Based Medicine; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Recovery of Function; Simendan; Treatment Outcome; Ventricular Function, Left	2013
Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials. Clinical research in cardiology : official journal of the German Cardiac Society, 2014, Volume: 103, Issue:7 Topics: Administration, Intravenous; Adult; Cardiotonic Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Time Factors	2014
[Organ-protection therapy. A new therapeutic approach for acute heart failure?]. Medicina clinica, 2014, Volume: 142 Suppl 1 Topics: Acute Disease; Amides; Benzazepines; Cardio-Renal Syndrome; Dobutamine; Fumarates; Heart Failure; Humans; Hydrazones; Inflammation; Kaplan-Meier Estimate; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Simendan; Therapies, Investigational; Tolvaptan	2014
Levosimendan: The current situation and new prospects. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2014, Volume: 33, Issue:12 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2014
Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis. Medical science monitor : international medical journal of experimental and clinical research, 2015, Mar-26, Volume: 21 Topics: Chronic Disease; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Stroke Volume	2015
Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis. Journal of cardiothoracic and vascular anesthesia, 2015, Volume: 29, Issue:6 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome	2015
Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. International journal of cardiology, 2016, Jan-01, Volume: 202 Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome	2016
Long-term intravenous inotropes in low-output terminal heart failure? Clinical research in cardiology : official journal of the German Cardiac Society, 2016, Volume: 105, Issue:6 Topics: Administration, Intravenous; Cardiac Output; Cardiac Output, Low; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Drug Administration Schedule; Heart Failure; Heart Transplantation; Humans; Hydrazones; Milrinone; Odds Ratio; Practice Guidelines as Topic; Pyridazines; Risk Factors; Simendan; Time Factors; Treatment Outcome; Waiting Lists	2016
The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. International journal of cardiology, 2016, Sep-01, Volume: 218 Topics: Acute Coronary Syndrome; Anti-Arrhythmia Agents; Drug Synergism; Heart Failure; Humans; Hydrazones; Practice Guidelines as Topic; Prognosis; Pyridazines; Simendan	2016
[Use of levosimendan in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2016, Volume: 23, Issue:8 Topics: Cardiac Output, Low; Cardiotonic Agents; Child; Extracorporeal Circulation; Heart Failure; Humans; Hydrazones; Postoperative Complications; Pyridazines; Simendan	2016
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International journal of cardiology, 2016, Nov-01, Volume: 222 Topics: Acute Disease; Anti-Arrhythmia Agents; Cardiotonic Agents; Clinical Trials as Topic; Expert Testimony; Heart; Heart Failure; Humans; Hydrazones; Muscle Contraction; Pyridazines; Simendan; Treatment Outcome	2016
A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites. Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:16 Topics: Calcium; Calmodulin; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Muscle Relaxation; Myocardial Contraction; Myosin Light Chains; Potassium Channels; Pyridazines; Simendan; Troponin C; Vascular Resistance	2018
Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:12 Topics: Cardiotonic Agents; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Pyridazines; Quality of Life; Simendan	2016
Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:8 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Oxidative Stress; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome	2008
Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International journal of cardiology, 2010, Feb-04, Volume: 138, Issue:3 Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan	2010
Management of heart failure: a brief review and selected update. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Diuretics; Heart Failure; Hemofiltration; Humans; Hydrazones; Natriuretic Peptide, Brain; Pacemaker, Artificial; Pyridazines; Simendan; Tolvaptan; Vasodilator Agents	2008
Cardiac Ca2+ signaling and Ca2+ sensitizers. Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:12 Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C	2008
Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:4 Topics: Calcium; Cardiotonic Agents; Contractile Proteins; Headache; Heart Failure; Humans; Hydrazones; Hypotension; Myocardium; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2008
Levosimendan for heart-operated patients: what is the state of the art? Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1 Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2009
Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. Current drug metabolism, 2009, Volume: 10, Issue:2 Topics: Animals; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Vasodilation	2009
Levosimendan. Indian pediatrics, 2009, Volume: 46, Issue:7 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2009
[Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment]. Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:7 Topics: Acute Disease; Algorithms; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Patient Selection; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Treatment Outcome	2009
[Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:10 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan	2009
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart failure reviews, 2009, Volume: 14, Issue:4 Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents	2009
A promising new inotrope: levosimendan. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Volume: 10, Issue:2 Topics: Calcium; Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction	2010
Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arquivos brasileiros de cardiologia, 2010, Volume: 95, Issue:2 Topics: Brazil; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Treatment Outcome; Vasodilator Agents	2010
Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties. International journal of clinical practice, 2010, Volume: 64, Issue:8 Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2010
[Therapeutic strategies in acute decompensated heart failure and cardiogenic shock]. Der Internist, 2010, Volume: 51, Issue:8 Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Combined Modality Therapy; Comorbidity; Critical Care; Cross-Sectional Studies; Diuretics; Emergency Service, Hospital; Heart Failure; Hospitalization; Humans; Hydrazones; Multicenter Studies as Topic; Myocardial Revascularization; Population Dynamics; Pyridazines; Risk Factors; Shock, Cardiogenic; Simendan; Vasodilator Agents	2010
Cardiovascular pharmacology: an update. Anesthesiology clinics, 2010, Volume: 28, Issue:4 Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea	2010
Levosimendan: calcium sensitizer and inodilator. Anesthesiology clinics, 2010, Volume: 28, Issue:4 Topics: Animals; Calcium; Cardiopulmonary Bypass; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Nitric Oxide; Pyridazines; Simendan; Vasodilator Agents; Ventricular Function, Left	2010
Levosimendan: from basic science to clinical trials. Recent patents on cardiovascular drug discovery, 2011, Volume: 6, Issue:1 Topics: Acute Disease; Animals; Calcium Channels; Cardiovascular Agents; Chronic Disease; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Oxygen Consumption; Potassium Channels; Pyridazines; Simendan; Translational Research, Biomedical; Treatment Outcome; Ventricular Function	2011
Current pharmacologic management of pediatric heart failure in congenital heart disease. Current vascular pharmacology, 2011, Volume: 9, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Diuretics; Heart Defects, Congenital; Heart Failure; Hemodynamics; Humans; Hydrazones; Incidence; Natriuretic Peptide, Brain; Pyridazines; Simendan	2011
Newer inotropes in pediatric heart failure. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:2 Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome	2011
Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Critical care medicine, 2012, Volume: 40, Issue:2 Topics: Cardiac Surgical Procedures; Critical Care; Critical Illness; Female; Heart Failure; Hospital Mortality; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Simendan; Treatment Outcome	2012
Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives. The Israel Medical Association journal : IMAJ, 2012, Volume: 14, Issue:3 Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Chronic Disease; Dobutamine; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hydrazones; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Pyridazines; Simendan	2012
[Calcium mobilizers and calcium sensitizers]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9 Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan	2011
The clinical effects of levosimendan are not attenuated by sulfonylureas. Scandinavian cardiovascular journal : SCJ, 2012, Volume: 46, Issue:6 Topics: Aged; Diabetes Mellitus; Drug Interactions; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypoglycemic Agents; KATP Channels; Logistic Models; Male; Middle Aged; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Simendan; Sulfonylurea Compounds; Treatment Outcome; Vasodilator Agents	2012
Levosimendan preoperative. Current pharmaceutical design, 2013, Volume: 19, Issue:22 Topics: Cardiac Surgical Procedures; Combined Modality Therapy; Heart Failure; Humans; Hydrazones; Preoperative Care; Pyridazines; Simendan; Vasodilator Agents	2013
The disconnect between phase II and phase III trials of drugs for heart failure. Nature reviews. Cardiology, 2013, Volume: 10, Issue:2 Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines	2013
New therapeutic choices in the management of acute congestive heart failure. Reviews in cardiovascular medicine, 2001, Volume: 2 Suppl 2 Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents	2001
Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? European journal of heart failure, 2003, Volume: 5, Issue:1 Topics: Calcium Channel Blockers; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; United States; Vasodilator Agents; Ventricular Dysfunction, Left	2003
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. American heart journal, 2003, Volume: 145, Issue:2 Suppl Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents	2003
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. American heart journal, 2003, Volume: 145, Issue:2 Suppl Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents	2003
The development of new medical treatments for acute decompensated heart failure. Heart failure monitor, 2002, Volume: 2, Issue:4 Topics: Acute Disease; Cardiotonic Agents; Cohort Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Multicenter Studies as Topic; Natriuretic Agents; Natriuretic Peptide, Brain; Placebos; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Endothelin; Simendan; Tetrazoles; Time Factors; Vasodilator Agents	2002
[Inotropic agents in advanced and refractory heart failure]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:1 Topics: Cardiotonic Agents; Dobutamine; Dopamine; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Treatment Failure; Treatment Outcome	2003
Levosimendan: a new dual-action drug in the treatment of acute heart failure. International journal of clinical practice, 2003, Volume: 57, Issue:5 Topics: Acute Disease; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Analysis; Treatment Outcome	2003
The role of Ca++-sensitizers for the treatment of heart failure. Current opinion in critical care, 2003, Volume: 9, Issue:5 Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Ischemia; Pyridazines; Simendan	2003
Levosimendan: implications for clinicians. Journal of clinical pharmacology, 2003, Volume: 43, Issue:10 Topics: Calcium; Cardiotonic Agents; Chronic Disease; Controlled Clinical Trials as Topic; Drug Interactions; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2003
Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure? Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 2 Topics: Acute Disease; Calcium; Calcium Channels, L-Type; Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vascular Resistance; Vasodilator Agents	2003
Considerations on the efficacy and safety of levosimendan in ischemic heart failure. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 2 Topics: Calcium Channels, L-Type; European Union; Heart Failure; Humans; Hydrazones; Morbidity; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome; United States; Vasodilator Agents	2003
The clinical experience with levosimendan in anesthesiology and in the intensive care unit. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 2 Topics: Adrenergic beta-Antagonists; Anesthesia; Calcium Channels, L-Type; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Intensive Care Units; Myocardial Contraction; Pyridazines; Shock, Cardiogenic; Simendan; Systole; Ventricular Dysfunction, Left	2003
Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs, 2003, Volume: 63, Issue:23 Topics: Acute Disease; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2003
New and emerging drug therapies for the management of acute heart failure. Internal medicine journal, 2003, Volume: 33, Issue:11 Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents; Vasopressins	2003
[Levosimendan. Clinical indications of a new vasoactive substance]. Der Anaesthesist, 2004, Volume: 53, Issue:2 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Salvage Therapy; Simendan	2004
[Levosimendan in cardiology and intensive care medicine]. Wiener klinische Wochenschrift, 2004, Jan-31, Volume: 116, Issue:1-2 Topics: Cardiotonic Agents; Critical Care; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Stunning; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Vasodilator Agents	2004
Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:1 Topics: Cardiotonic Agents; Drug Interactions; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Pyridazines; Randomized Controlled Trials as Topic; Safety; Simendan; Time Factors; Vasodilator Agents	2004
New therapies for heart failure. RN, 2004, Volume: 67, Issue:3 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States	2004
New positive inotropic agents in the treatment of left ventricular dysfunction. Italian heart journal : official journal of the Italian Federation of Cardiology, 2004, Volume: 5 Suppl 6 Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left	2004
Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department. Emergency medicine Australasia : EMA, 2004, Volume: 16, Issue:1 Topics: Acute Disease; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Critical Illness; Developed Countries; Diuretics; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Oxygen Inhalation Therapy; Patient Selection; Pulmonary Edema; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents	2004
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Molecular and cellular biochemistry, 2004, Volume: 266, Issue:1-2 Topics: Animals; Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Protein Binding; Pyridazines; Simendan; Tropomyosin; Troponin C; Troponin I; Troponin T	2004
Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Current pharmaceutical design, 2005, Volume: 11, Issue:4 Topics: Administration, Oral; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Time Factors; Vasodilator Agents	2005
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency]. Deutsche medizinische Wochenschrift (1946), 2005, Apr-15, Volume: 130, Issue:15 Topics: Actin Cytoskeleton; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; Myocardium; Oxygen Consumption; Pyridazines; Quinolines; Simendan; Thiadiazines	2005
Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovascular drug reviews, 2005,Spring, Volume: 23, Issue:1 Topics: Animals; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome	2005
Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Current medicinal chemistry. Cardiovascular and hematological agents, 2005, Volume: 3, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Contraindications; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2005
[Levosimendan, a revolution in the world of inotropic agents?]. Revue medicale suisse, 2005, May-25, Volume: 1, Issue:21 Topics: Anti-Arrhythmia Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan	2005
An emerging role for calcium sensitisation in the treatment of heart failure. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:6 Topics: Animals; Calcium Signaling; Clinical Trials as Topic; Drugs, Investigational; Heart Failure; Humans; Hydrazones; Myocytes, Cardiac; Pyridazines; Simendan	2005
Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Current heart failure reports, 2004, Volume: 1, Issue:3 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Heart Function Tests; Humans; Hydrazones; Infusions, Intravenous; Male; Maximum Tolerated Dose; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome; Vasodilator Agents	2004
[The novelty in the treatment of heart failure]. Medicina (Kaunas, Lithuania), 2005, Volume: 41, Issue:7 Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Multicenter Studies as Topic; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan; Vasodilator Agents	2005
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. International journal of cardiology, 2005, Sep-01, Volume: 103, Issue:3 Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2005
The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:3 Topics: Actin Cytoskeleton; Animals; Calcium; Cardiotonic Agents; Energy Metabolism; Heart Failure; Humans; Hydrazones; Mice; Mice, Transgenic; Myocardial Contraction; Myocardium; Phosphorylation; Pyridazines; Simendan; Ventricular Function, Left	2005
Cardioprotection: a new paradigm in the management of acute heart failure syndromes. The American journal of cardiology, 2005, Sep-19, Volume: 96, Issue:6A Topics: Acute Disease; Animals; Cardiotonic Agents; Cells, Cultured; Heart Failure; Humans; Hydrazones; Hydrogen Peroxide; Myocytes, Cardiac; Oxidative Stress; Pyridazines; Rats; Simendan; Syndrome	2005
Pharmacology of new agents for acute heart failure syndromes. The American journal of cardiology, 2005, Sep-19, Volume: 96, Issue:6A Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Pyridazines; Pyridines; Simendan; Syndrome; Tetrazoles; Tolvaptan; Vasodilator Agents	2005
Randomized clinical trials with levosimendan. The American journal of cardiology, 2005, Sep-19, Volume: 96, Issue:6A Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome	2005
European experience on the practical use of levosimendan in patients with acute heart failure syndromes. The American journal of cardiology, 2005, Sep-19, Volume: 96, Issue:6A Topics: Acute Disease; Cardiotonic Agents; Europe; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome	2005
Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:11 Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome	2005
[Levosimendan]. Deutsche medizinische Wochenschrift (1946), 2005, Oct-28, Volume: 130, Issue:43 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Vasodilator Agents	2005
Levosimendan for the treatment of acute heart failure syndromes. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:15 Topics: Acute Disease; Animals; Heart Failure; Humans; Hydrazones; Pyridazines; Radiography; Simendan; Syndrome	2005
Levosimendan: dual mechanisms for acute heart failure...and beyond? Minerva cardioangiologica, 2005, Volume: 53, Issue:6 Topics: Acute Disease; Calcium; Cardiac Output; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pulmonary Wedge Pressure; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; Vasodilator Agents	2005
[Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?]. Ugeskrift for laeger, 2006, Jan-16, Volume: 168, Issue:3 Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan	2006
Ca2+-sensitisers--a promising option to treat heart failure? Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:6 Topics: Calcium; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2005
Optimizing outcomes in the patient with acute decompensated heart failure. American heart journal, 2006, Volume: 151, Issue:3 Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure	2006
[Medical and ventilatory treatment of acute heart failure]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2006, Mar-09, Volume: 126, Issue:6 Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Continuous Positive Airway Pressure; Diuretics; Dobutamine; Furosemide; Heart Failure; Humans; Hydrazones; Isosorbide Dinitrate; Natriuretic Agents; Natriuretic Peptide, Brain; Nitric Oxide Donors; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridazines; Simendan; Vasodilator Agents	2006
Newer approaches to the pharmacological management of heart failure. Current opinion in anaesthesiology, 2006, Volume: 19, Issue:1 Topics: Calcium Signaling; Cardiotonic Agents; Cardiovascular Agents; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyridazines; Pyridines; Simendan; Tetrazoles	2006
Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:2 Topics: Adenosine Triphosphate; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Models, Biological; Myocardial Stunning; Potassium Channels; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Ventricular Dysfunction	2006
Evidence-based use of levosimendan in different clinical settings. European heart journal, 2006, Volume: 27, Issue:16 Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Child; Heart Failure; Humans; Hydrazones; Intraoperative Care; Myocardial Ischemia; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan	2006
A review of levosimendan in the treatment of heart failure. Vascular health and risk management, 2006, Volume: 2, Issue:4 Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardiotonic Agents; Coronary Circulation; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Matrix Metalloproteinases; Myocardial Contraction; Myocardial Stunning; Neurosecretory Systems; Practice Guidelines as Topic; Pyridazines; Simendan; Treatment Outcome; Ventricular Remodeling	2006
Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacology & therapeutics, 2007, Volume: 114, Issue:2 Topics: Calcium; Cardiac Output; Cardiotonic Agents; Drug Interactions; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Simendan; Vasodilation; Vasodilator Agents	2007
The utility of levosimendan in the treatment of heart failure. Annals of medicine, 2007, Volume: 39, Issue:1 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Stroke Volume; Survival Rate; Treatment Outcome; Vasodilation	2007
The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:5 Topics: Aged; Biological Availability; Calcium Channels; Cardiotonic Agents; Dobutamine; Half-Life; Heart Failure; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Tissue Distribution; Treatment Outcome	2007
Classical inotropes and new cardiac enhancers. Heart failure reviews, 2007, Volume: 12, Issue:2 Topics: Algorithms; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Hydrazones; Milrinone; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome	2007
[Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects]. Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5 Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stimulation, Chemical; Survival Rate	2007
[Calcium sensitizer agents in heart failure therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5 Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stimulation, Chemical	2007
[Combination therapy with PDE III inhibitor for heart failure]. Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan	2007
[Levosimendan for treatment of heart failure]. Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5 Topics: Blood Pressure; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Heart Rate; Humans; Hydrazones; Inflammation Mediators; Natriuretic Peptide, Brain; Pyridazines; Shock, Cardiogenic; Simendan	2007
Clinical pharmacology of levosimendan. Clinical pharmacokinetics, 2007, Volume: 46, Issue:7 Topics: Area Under Curve; Cardiotonic Agents; Clinical Trials as Topic; Half-Life; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Molecular Structure; Pyridazines; Simendan; Treatment Outcome	2007
Medical support and surgery of the failing heart: levosimendan. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2007, Volume: 96, Issue:2 Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Intraoperative Care; Pyridazines; Simendan	2007
Pharmacologic therapy for acute heart failure. Cardiology clinics, 2007, Volume: 25, Issue:4 Topics: Antidiuretic Hormone Receptor Antagonists; Catecholamines; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Natriuretic Agents; Natriuretic Peptide, Brain; Natriuretic Peptides; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Vasodilator Agents	2007
Inoprotection: the perioperative role of levosimendan. Anaesthesia and intensive care, 2007, Volume: 35, Issue:6 Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Coronary Artery Bypass; Heart Failure; Humans; Hydrazones; Ischemic Preconditioning, Myocardial; Myocardial Contraction; Perioperative Care; Potassium Channels; Pyridazines; Simendan	2007
Inotropes in the management of acute heart failure. Critical care medicine, 2008, Volume: 36, Issue:1 Suppl Topics: Acute Disease; Cardiac Myosins; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Patient Selection; Pyridazines; Simendan	2008
New pharmacologic therapies for acute heart failure. Critical care medicine, 2008, Volume: 36, Issue:1 Suppl Topics: Acute Disease; Adenosine; Adenosine Triphosphatases; Antidiuretic Hormone Receptor Antagonists; Cardiac Myosins; Cardiotonic Agents; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Peptides; Pyridazines; Simendan	2008
Levosimendan: current status and future prospects. Current opinion in anaesthesiology, 2008, Volume: 21, Issue:1 Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Postoperative Complications; Pyridazines; Shock, Septic; Simendan; Ventricular Dysfunction, Right	2008
Levosimendan: a novel agent in heart failure. Recent patents on cardiovascular drug discovery, 2006, Volume: 1, Issue:2 Topics: Animals; Apoptosis; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Vasodilator Agents	2006
Overview of emerging pharmacologic agents for acute heart failure syndromes. European journal of heart failure, 2008, Volume: 10, Issue:2 Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents	2008
Levosimendan use in several scenarios of acute heart failure. Arquivos brasileiros de cardiologia, 2008, Volume: 90, Issue:3 Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Contraindications; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypotension; Ischemia; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Syndrome; Vasodilator Agents	2008
Role of levosimendan in sepsis and septic shock. Current opinion in anaesthesiology, 2008, Volume: 21, Issue:2 Topics: Animals; Calcium; Dose-Response Relationship, Drug; Drug Interactions; Endotoxemia; Heart Failure; Humans; Hydrazones; Potassium Channels; Pyridazines; Sepsis; Shock, Septic; Simendan	2008
Calcium sensitising agents in heart failure. Drugs & aging, 1998, Volume: 12, Issue:3 Topics: Aged; Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	1998
[Ca2+ sensitizers]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2000, Volume: 45, Issue:6 Suppl Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dihydropyridines; Drug Design; Heart Failure; Humans; Hydrazones; Myocardium; Pyridazines; Signal Transduction; Simendan	2000
Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure. Current cardiology reports, 2000, Volume: 2, Issue:3 Topics: Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Vasodilator Agents	2000
Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:5 Topics: Calcium; Drug and Narcotic Control; Heart Failure; Hydrazones; Pyridazines; Simendan; Vasodilator Agents	2001
Levosimendan. Drugs, 2001, Volume: 61, Issue:5 Topics: Biological Availability; Cardiotonic Agents; Coronary Circulation; Half-Life; Heart Failure; Humans; Hydrazones; Protein Binding; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2001
New pharmacological strategies for the treatment of heart failure. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Endothelin-1; Heart Failure; Humans; Hydrazones; Muscle Proteins; Neprilysin; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Sulfonamides; Tumor Necrosis Factor-alpha	2001
Levosimendan: a new era for inodilator therapy for heart failure? Current opinion in cardiology, 2002, Volume: 17, Issue:3 Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left	2002

Trials

109 trial(s) available for simendan and Cardiac Failure

Article	Year
Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in medical sciences, 2022, Volume: 67, Issue:1 Topics: Cardiotonic Agents; Double-Blind Method; Heart Failure; Humans; Simendan; Stroke Volume; Treatment Outcome	2022
Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC heart failure, 2021, Volume: 8, Issue:6 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2021
Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study. BMC cardiovascular disorders, 2022, 03-29, Volume: 22, Issue:1 Topics: Cardiotonic Agents; Drugs, Chinese Herbal; Heart Failure; Humans; Hydrazones; Hypotension; Prospective Studies; Pyridazines; Simendan; Single-Blind Method	2022
Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain. Revista espanola de cardiologia (English ed.), 2020, Volume: 73, Issue:5 Topics: Administration, Intravenous; Aged; Aged, 80 and over; Ambulatory Care; Cardiotonic Agents; Costs and Cost Analysis; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Outpatients; Risk Factors; Simendan; Spain; Treatment Outcome	2020
Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2020, Volume: 40, Issue:5 Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Female; Heart Failure; Hip Fractures; Humans; Male; Malondialdehyde; Natriuretic Peptide, Brain; Nitric Oxide; Simendan; Treatment Outcome	2020
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial. JACC. Heart failure, 2021, Volume: 9, Issue:5 Topics: Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Simendan; Stroke Volume	2021
Effects of levosimendan in patients with severe functional mitral regurgitation undergoing MitraClip implantation. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:9 Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Female; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Male; Middle Aged; Mitral Valve Insufficiency; Pyridazines; Simendan	2017
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. European journal of heart failure, 2018, Volume: 20, Issue:7 Topics: Aged; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Injections, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Protein Precursors; Retrospective Studies; Simendan; Stroke Volume; Treatment Outcome	2018
Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. ESC heart failure, 2018, Volume: 5, Issue:3 Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Simendan; Treatment Outcome	2018
Comparison of Levosimendan and Milrinone for ECLS Weaning in Patients After Cardiac Surgery-A Retrospective Before-and-After Study. Journal of cardiothoracic and vascular anesthesia, 2018, Volume: 32, Issue:5 Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Extracorporeal Membrane Oxygenation; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Middle Aged; Milrinone; Postoperative Care; Retrospective Studies; Shock, Cardiogenic; Simendan; Switzerland	2018
PREVENTION OF HEART FAILURE PATIENTS WITH DECREASED EJECTION FRACTION IN NON-CARDIAC SURGERY: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION?. Anesteziologiia i reanimatologiia, 2016, Volume: 61, Issue:6 Topics: Aged; Anesthesia, General; Aorta; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Perioperative Period; Prospective Studies; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome	2016
Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial. Journal of the American Heart Association, 2018, 08-21, Volume: 7, Issue:16 Topics: Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hemodynamic Monitoring; Hemodynamics; Humans; Male; Middle Aged; p-Aminohippuric Acid; Renal Circulation; Renal Insufficiency; Renal Plasma Flow; Simendan	2018
Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC heart failure, 2019, Volume: 6, Issue:1 Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Heart Failure; Humans; Infusions, Intravenous; Patient Discharge; Simendan; Stroke Volume; Treatment Outcome	2019
Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovascular therapeutics, 2013, Volume: 31, Issue:2 Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Pressure; Cardiotonic Agents; Chi-Square Distribution; China; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Hospitalization; Humans; Hydrazones; Infusions, Intravenous; Kidney Diseases; Linear Models; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Urination; Ventricular Function, Left	2013
Intermittent levosimendan treatment in patients with severe congestive heart failure. Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:7 Topics: Aged; Cardiotonic Agents; Drug Administration Schedule; Exercise Test; Exercise Tolerance; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Longitudinal Studies; Male; Middle Aged; Oxygen; Pyridazines; Severity of Illness Index; Simendan; Surveys and Questionnaires; Treatment Outcome	2013
Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:6 Topics: Cardiotonic Agents; Double-Blind Method; Drug Administration Schedule; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Simendan	2013
Impact of levosimendan on right ventricular functions by using novel tissue Doppler derived indices in patients with ischaemic left ventricular failure. Kardiologia polska, 2013, Volume: 71, Issue:10 Topics: Cardiotonic Agents; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Right	2013
Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Medical science monitor : international medical journal of experimental and clinical research, 2014, Feb-19, Volume: 20 Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Interleukin-1beta; Interleukin-2; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Tumor Necrosis Factor-alpha; Turkey; Vasodilator Agents	2014
Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC. Heart failure, 2013, Volume: 1, Issue:2 Topics: Cardiotonic Agents; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan	2013
Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology, 2014, Volume: 128, Issue:2 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome	2014
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure. Cardiology journal, 2015, Volume: 22, Issue:1 Topics: Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Pyridazines; Recovery of Function; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Turkey; Ventricular Dysfunction, Left; Ventricular Function, Left	2015
Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. European journal of heart failure, 2014, Volume: 16, Issue:8 Topics: Aged; Aged, 80 and over; Ambulatory Care; Cardiotonic Agents; Disease-Free Survival; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome	2014
The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. Clinical transplantation, 2014, Volume: 28, Issue:10 Topics: Adult; Cardiotonic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Kidney; Kidney Function Tests; Male; Middle Aged; Pilot Projects; Prognosis; Pyridazines; Risk Factors; Simendan; Survival Rate	2014
Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. PloS one, 2014, Volume: 9, Issue:11 Topics: Aged; Biomarkers; C-Reactive Protein; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Male; Matrix Metalloproteinase 9; Middle Aged; Morpholines; Myocardial Contraction; Myocardial Infarction; Pyridazines; Receptors, Interleukin-6; Recovery of Function; Simendan; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Ventricular Function, Left	2014
Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. The American journal of the medical sciences, 2015, Volume: 349, Issue:5 Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Mortality; Natriuretic Peptide, Brain; Patient Readmission; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome	2015
Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study. Cardiovascular therapeutics, 2015, Volume: 33, Issue:4 Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Critical Illness; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Recovery of Function; Severity of Illness Index; Simendan; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left	2015
Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients. Medical science monitor : international medical journal of experimental and clinical research, 2015, Aug-20, Volume: 21 Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Asian People; China; Creatinine; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome	2015
Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study. Anatolian journal of cardiology, 2015, Volume: 15, Issue:8 Topics: Adolescent; Adult; Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Serum Albumin; Serum Albumin, Human; Simendan; Treatment Outcome; Turkey; Young Adult	2015
Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. International journal of cardiology, 2016, Jul-15, Volume: 215 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Dobutamine; Drug Therapy, Combination; Female; Finland; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Proportional Hazards Models; Pyridazines; Retrospective Studies; Simendan; Survival Analysis; Treatment Outcome	2016
Systolic mitral annulus velocity is a sensitive index for changes in left ventricular systolic function during inotropic therapy in patients with acute heart failure. European heart journal. Acute cardiovascular care, 2018, Volume: 7, Issue:4 Topics: Acute Disease; Aged; Blood Flow Velocity; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Doppler, Color; Electrocardiography; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Male; Mitral Valve; Pyridazines; Reproducibility of Results; Simendan; ST Elevation Myocardial Infarction; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left	2018
Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz, 2008, Volume: 33, Issue:5 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Right	2008
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovascular therapeutics, 2008,Fall, Volume: 26, Issue:3 Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Propanolamines; Pyridazines; Simendan; Time Factors; Treatment Outcome	2008
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:8 Topics: Acetamides; Administration, Oral; Aged; Area Under Curve; Cardiotonic Agents; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Magnetocardiography; Male; Middle Aged; Pyridazines; Simendan	2008
Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. European journal of heart failure, 2008, Volume: 10, Issue:12 Topics: Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Psychometrics; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Surveys and Questionnaires	2008
Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. International journal of cardiology, 2010, Feb-18, Volume: 139, Issue:1 Topics: Acute Disease; Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Readmission; Predictive Value of Tests; Pyridazines; Sensitivity and Specificity; Simendan; Ultrasonography	2010
Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clinical cardiology, 2008, Volume: 31, Issue:12 Topics: Aged; Atrial Function, Left; Blood Pressure; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Pressure	2008
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. European journal of heart failure, 2009, Volume: 11, Issue:3 Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Cause of Death; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Survival Rate; Treatment Outcome	2009
Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart and vessels, 2009, Volume: 24, Issue:1 Topics: Aged; Cardiotonic Agents; Diastole; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Systole; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Right	2009
Effectiveness and safety of levosimendan in clinical practice. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2009, Volume: 28, Issue:2 Topics: Acute Disease; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Systole; Vasodilator Agents	2009
The costs of treating acute heart failure: an economic analysis of the SURVIVE trial. Journal of medical economics, 2008, Volume: 11, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Female; Health Expenditures; Heart Failure; Humans; Hydrazones; Length of Stay; Male; Middle Aged; Patient Admission; Pyridazines; Simendan	2008
Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. The European journal of health economics : HEPAC : health economics in prevention and care, 2010, Volume: 11, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Australia; Cardiotonic Agents; Cost-Benefit Analysis; Female; Heart Failure; Hospital Costs; Humans; Hydrazones; Israel; Length of Stay; Male; Middle Aged; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Analysis; Treatment Outcome; United States; Young Adult	2010
Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. The Canadian journal of cardiology, 2009, Volume: 25, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Atrial Function, Left; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome; Young Adult	2009
Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording. Acute cardiac care, 2010, Volume: 12, Issue:1 Topics: Acute Disease; Cardiotonic Agents; Drug Monitoring; Echocardiography; Electromyography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Microelectrodes; Middle Aged; Plethysmography; Pyridazines; Simendan; Single-Blind Method; Statistics, Nonparametric; Sympathetic Nervous System; Treatment Outcome	2010
Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). European journal of heart failure, 2010, Volume: 12, Issue:2 Topics: Cardiotonic Agents; Double-Blind Method; Female; Health Status Indicators; Heart Failure; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Outpatients; Pulsatile Flow; Pyridazines; Quality of Life; Research Design; Simendan; Surveys and Questionnaires	2010
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. European journal of heart failure, 2010, Volume: 12, Issue:4 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Antihypertensive Agents; Cardiotonic Agents; Confidence Intervals; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Odds Ratio; Perfusion; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vasodilator Agents	2010
[Study evaluating the impact of a combination of inotropic support and heart rate control on prognosis and stabilization rate in patients with decompensated chronic heart failure (LEGION)]. Terapevticheskii arkhiv, 2010, Volume: 82, Issue:3 Topics: Benzazepines; Blood Pressure; Cardiotonic Agents; Catheterization, Swan-Ganz; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Ivabradine; Male; Middle Aged; Monitoring, Physiologic; Myocardial Contraction; Pilot Projects; Prognosis; Prospective Studies; Pyridazines; Simendan; Treatment Outcome	2010
Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:9 Topics: Aged; Cardiography, Impedance; Cardiotonic Agents; Chronic Disease; Diastole; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Italy; Male; Middle Aged; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Pilot Projects; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left	2010
Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. Heart and vessels, 2010, Volume: 25, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Chronic Disease; Down-Regulation; Female; Heart Failure; Humans; Hydrazones; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Turkey	2010
[Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure]. Zhonghua xin xue guan bing za zhi, 2010, Volume: 38, Issue:6 Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome	2010
Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy. Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2 Topics: Aged; Anti-Arrhythmia Agents; Biomarkers; Cardiomyopathies; DNA; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left	2011
Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure. Arquivos brasileiros de cardiologia, 2010, Volume: 95, Issue:6 Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Female; Heart Conduction System; Heart Failure; Humans; Hydrazones; Male; Muscle Contraction; Pyridazines; Simendan; Statistics, Nonparametric	2010
Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients. Scandinavian cardiovascular journal : SCJ, 2011, Volume: 45, Issue:2 Topics: Acetamides; Acetylation; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents	2011
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Dobutamine; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Parenteral; Male; Middle Aged; Pyridazines; Risk Factors; Simendan; Tachycardia, Ventricular; Ventricular Premature Complexes	2010
Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study. International journal of cardiology, 2011, Mar-03, Volume: 147, Issue:2 Topics: Cytokines; Double-Blind Method; Heart Failure; Humans; Hydrazones; Male; Placebos; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents	2011
Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Critical care medicine, 2011, Volume: 39, Issue:5 Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiotonic Agents; Confidence Intervals; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Patient Discharge; Proportional Hazards Models; Pyridazines; Reference Values; Risk Assessment; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome	2011
Oral levosimendan improves filling pressure and systolic function during long-term treatment. Scandinavian cardiovascular journal : SCJ, 2011, Volume: 45, Issue:2 Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Systole; Time Factors; Treatment Outcome; Vasodilator Agents	2011
Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients. Medical science monitor : international medical journal of experimental and clinical research, 2011, Feb-25, Volume: 17, Issue:3 Topics: Aged; Cardiac Output; Case-Control Studies; Echocardiography; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors	2011
Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Critical care medicine, 2011, Volume: 39, Issue:10 Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Failure; Heart Valve Diseases; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan	2011
[Efficacy of levosimendan vs dopamine in patients with resistant cardiac failure]. Terapevticheskii arkhiv, 2011, Volume: 83, Issue:6 Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Dopamine; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pilot Projects; Prognosis; Pyridazines; Simendan	2011
Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure. Cardiovascular therapeutics, 2013, Volume: 31, Issue:2 Topics: Adult; Brazil; Cardiovascular Agents; Chemoreceptor Cells; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypercapnia; Hyperventilation; Hypoxia; Infusions, Intravenous; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Recombinant Proteins; Respiratory Rate; Simendan; Time Factors; Treatment Outcome	2013
[The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study]. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2012, Volume: 12, Issue:1 Topics: Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Prospective Studies; Pyridazines; Simendan; Treatment Outcome	2012
[Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure]. Zhonghua yi xue za zhi, 2012, Feb-28, Volume: 92, Issue:8 Topics: Adolescent; Adult; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Young Adult	2012
[Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure]. Zhonghua xin xue guan bing za zhi, 2012, Volume: 40, Issue:2 Topics: Aged; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome	2012
Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:5 Topics: Aged; Calcium; Chronic Disease; Data Interpretation, Statistical; Diuretics; Drug Administration Schedule; Female; Furosemide; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Mortality; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Function	2012
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European journal of heart failure, 2013, Volume: 15, Issue:5 Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Norway; Percutaneous Coronary Intervention; Pyridazines; Simendan; Treatment Outcome	2013
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). European heart journal, 2002, Volume: 23, Issue:18 Topics: Acute Disease; Aged; Analysis of Variance; Cardiotonic Agents; Double-Blind Method; Drug Evaluation; Endpoint Determination; Female; Heart Failure; Humans; Hydrazones; Hypotension; Male; Myocardial Infarction; Prospective Studies; Pyridazines; Risk Factors; Safety; Simendan; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left	2002
Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. International journal of clinical pharmacology and therapeutics, 2002, Volume: 40, Issue:10 Topics: Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Time Factors	2002
Sustained hemodynamic effects of intravenous levosimendan. Circulation, 2003, Jan-07, Volume: 107, Issue:1 Topics: Cardiotonic Agents; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Kinetics; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents	2003
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. European journal of heart failure, 2003, Volume: 5, Issue:1 Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Double-Blind Method; Europe; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Life Expectancy; Male; Middle Aged; Patient Admission; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome	2003
Population pharmacokinetics of levosimendan in patients with congestive heart failure. British journal of clinical pharmacology, 2003, Volume: 55, Issue:6 Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan	2003
Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:8 Topics: Administration, Oral; Adult; Aged; Blood Pressure; Electric Stimulation; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Pyridazines; Simendan; Time Factors; Vasodilation	2003
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 2 Topics: Adrenergic beta-Agonists; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Death, Sudden, Cardiac; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Morbidity; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Risk Factors; Severity of Illness Index; Shock, Cardiogenic; Simendan; Stroke Volume; Survival Analysis; Time; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left	2003
Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. British journal of clinical pharmacology, 2004, Volume: 57, Issue:4 Topics: Acetamides; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Protein Binding; Pyridazines; Simendan	2004
Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. The American journal of cardiology, 2004, May-15, Volume: 93, Issue:10 Topics: Adjuvants, Immunologic; Aged; Cardiotonic Agents; Fas Ligand Protein; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Pyridazines; Simendan; Ventricular Function, Left	2004
Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. Journal of clinical pharmacology, 2004, Volume: 44, Issue:10 Topics: Administration, Oral; Analysis of Variance; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan	2004
Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. The American journal of cardiology, 2004, Nov-15, Volume: 94, Issue:10 Topics: Administration, Oral; Cardiac Output; Cardiotonic Agents; Diuretics; Dobutamine; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Simendan	2004
Levosimendan in daily intensive care practice--the experience of 15 centers. Background, methods and organization of the PORTLAND study. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2004, Volume: 23, Issue:11 Topics: Critical Care; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Prospective Studies; Pyridazines; Simendan; Vasodilator Agents	2004
Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation, 2005, Mar-29, Volume: 111, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardium; Oxygen Consumption; Pyridazines; Regional Blood Flow; Simendan; Vascular Resistance; Vasodilation; Vasomotor System; Ventricular Dysfunction, Left	2005
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. European journal of heart failure, 2005, Volume: 7, Issue:5 Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha	2005
Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. The American journal of cardiology, 2005, Aug-01, Volume: 96, Issue:3 Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Ventricular Dysfunction, Left	2005
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. European journal of heart failure, 2005, Volume: 7, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprostadil; Biomarkers; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Vasodilator Agents	2005
Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:6 Topics: Aged; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Matrix Metalloproteinase 2; Placebos; Pyridazines; Simendan; Treatment Outcome	2005
Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. European journal of heart failure, 2006, Volume: 8, Issue:8 Topics: Aged; fas Receptor; Female; Heart Failure; Humans; Hydrazones; Inflammation; Infusions, Parenteral; Interleukin-6; Male; Pyridazines; Receptors, Tumor Necrosis Factor, Type I; Simendan; Solubility; Time Factors; Tumor Necrosis Factor-alpha	2006
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. The American journal of cardiology, 2006, Jul-01, Volume: 98, Issue:1 Topics: Aged; Apoptosis; Cardiotonic Agents; Chronic Disease; Dobutamine; Echocardiography; Fas Ligand Protein; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors	2006
Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. European journal of heart failure, 2007, Volume: 9, Issue:1 Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebos; Pulmonary Circulation; Pyridazines; Simendan; Systole; Time Factors; Ventricular Dysfunction, Left	2007
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. European journal of heart failure, 2007, Volume: 9, Issue:2 Topics: Adrenergic beta-Antagonists; Alprostadil; Cardiotonic Agents; Drug Interactions; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents	2007
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart (British Cardiac Society), 2006, Volume: 92, Issue:12 Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Cytokines; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Immunity, Cellular; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Treatment Outcome; Troponin T; Vasodilator Agents; Ventricular Dysfunction, Left	2006
Effects of levosimendan on right ventricular function in patients with advanced heart failure. The American journal of cardiology, 2006, Dec-01, Volume: 98, Issue:11 Topics: Blood Pressure; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Interleukin-10; Interleukin-6; Male; Middle Aged; Natriuretic Peptides; Pulmonary Artery; Pyridazines; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right	2006
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. The American journal of cardiology, 2006, Dec-15, Volume: 98, Issue:12 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left	2006
Effect of levosimendan on E/E' ratio in patients with ischemic heart failure. International journal of cardiology, 2008, Jan-11, Volume: 123, Issue:2 Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyridazines; Simendan; Single-Blind Method	2008
Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin. International journal of cardiology, 2008, Mar-28, Volume: 125, Issue:1 Topics: Adult; Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Function, Left	2008
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA, 2007, May-02, Volume: 297, Issue:17 Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Analysis	2007
Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008, Volume: 197, Issue:1 Topics: Aged; Chronic Disease; Endothelium, Vascular; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Severity of Illness Index; Simendan; Solubility; Stroke Volume; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents	2008
Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:4 Topics: Aged; Cardiotonic Agents; Exercise Tolerance; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Natriuretic Peptide, Brain; Psychometrics; Pyridazines; Quality of Life; Simendan; Stress, Psychological; Surveys and Questionnaires	2007
Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. Journal of cardiac failure, 2007, Volume: 13, Issue:6 Topics: Biomarkers; Cardiotonic Agents; Creatinine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Hydrazones; Infusions, Intravenous; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Treatment Outcome; Waiting Lists	2007
[Clinical experience with levosimendan in the emergency department of a tertiary care hospital]. Revista espanola de cardiologia, 2007, Volume: 60, Issue:8 Topics: Acute Disease; Aged; Cardiotonic Agents; Emergency Service, Hospital; Emergency Treatment; Female; Heart Failure; Humans; Hydrazones; Male; Prospective Studies; Pyridazines; Simendan	2007
Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis, 2007, Volume: 195, Issue:2 Topics: Aged; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Hydrazones; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Protein Carbonylation; Pyridazines; Simendan; Stroke Volume; Tyrosine	2007
Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. International journal of clinical practice, 2008, Volume: 62, Issue:2 Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right	2008
Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:6 Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Male; Middle Aged; Pyridazines; Simendan; Urination	2007
Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. European journal of heart failure, 2007, Volume: 9, Issue:12 Topics: Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Regional Blood Flow; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left	2007
Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience. Heart, lung & circulation, 2008, Volume: 17, Issue:3 Topics: Adult; Aged; Ambulatory Care; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan	2008
Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Arquivos brasileiros de cardiologia, 2008, Volume: 90, Issue:3 Topics: Adolescent; Adrenergic beta-Agonists; Adult; Brazil; Cardiotonic Agents; Dyspnea; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydrazones; Infusions, Intravenous; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Prospective Studies; Pyridazines; Quality of Life; Simendan; Treatment Outcome; Vasodilator Agents; Young Adult	2008
Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. European journal of clinical pharmacology, 1996, Volume: 49, Issue:6 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cardiac Output; Cardiotonic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Echocardiography; Electrocardiography, Ambulatory; Half-Life; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intravenous; Male; Middle Aged; Myocardial Contraction; Pyridazines; Simendan	1996
Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. Journal of cardiovascular pharmacology, 1995, Volume: 26 Suppl 1 Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Proteins; Carbon Radioisotopes; Cardiotonic Agents; Erythrocytes; Feces; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Protein Binding; Pyridazines; Reference Values; Saliva; Simendan; Troponin C	1995
Heart failure update. European journal of heart failure, 1999, Volume: 1, Issue:3 Topics: Blood Pressure; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardial Infarction; Pyridazines; Safety; Simendan; Survival Rate; Treatment Outcome	1999
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation, 2000, Oct-31, Volume: 102, Issue:18 Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Heart Function Tests; Heart Rate; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents	2000
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. Journal of the American College of Cardiology, 2000, Nov-15, Volume: 36, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Norepinephrine; Pyridazines; Simendan	2000
Myocardial efficiency during levosimendan infusion in congestive heart failure. Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:5 Topics: Cardiotonic Agents; Catheterization, Swan-Ganz; Coronary Vessels; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Oxygen Consumption; Pyridazines; Simendan; Tomography, Emission-Computed; Ultrasonography	2000
Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. Journal of clinical pharmacology, 2002, Volume: 42, Issue:1 Topics: Aged; Analysis of Variance; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiotonic Agents; Chronic Disease; Electrocardiography; Erythrocyte Indices; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan	2002

Other Studies

212 other study(ies) available for simendan and Cardiac Failure

Article	Year
Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance. The Libyan journal of medicine, 2021, Volume: 16, Issue:1 Topics: Diuretics; Heart Failure; Heart Rate; Humans; Natriuretic Peptide, Brain; Simendan; Treatment Outcome	2021
Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study. Journal of cardiovascular pharmacology, 2022, 01-01, Volume: 79, Issue:1 Topics: Aged; Ambulatory Care; Cardiovascular Agents; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Outpatients; Pilot Projects; Predictive Value of Tests; Recovery of Function; Simendan; Time Factors; Treatment Outcome	2022
Levosimendan and Continuous Outpatient Support With Inotropes in Patients With Advanced Heart Failure: A Single-Centre Descriptive Study. Journal of cardiovascular pharmacology, 2022, 04-01, Volume: 79, Issue:4 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Outpatients; Retrospective Studies; Simendan	2022
Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients. ESC heart failure, 2022, Volume: 9, Issue:2 Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Pyridazines; Quality of Life; Simendan; Stroke Volume; Ventricular Function, Left	2022
Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction. Journal of cardiovascular pharmacology, 2022, 06-01, Volume: 79, Issue:6 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney Diseases; Milrinone; Pyridazines; Retrospective Studies; Simendan	2022
Effect of levosimendan infusion prior to left ventricular assist device implantation on right ventricular failure. Journal of cardiothoracic surgery, 2022, Jun-16, Volume: 17, Issue:1 Topics: Heart Failure; Heart-Assist Devices; Humans; Retrospective Studies; Simendan; Ventricular Dysfunction, Right	2022
Acute‑on‑chronic pulmonary embolism‑induced right ventricular failure salvaged by combined catheter‑directed therapy and levosimendan infusion. Polish archives of internal medicine, 2022, 10-21, Volume: 132, Issue:10 Topics: Catheters; Heart Failure; Humans; Pulmonary Embolism; Simendan; Ventricular Dysfunction, Right	2022
Levosimendan for acute right heart failure in COVID-19: another arrow in our quiver? European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:15 Topics: Aged; COVID-19; COVID-19 Drug Treatment; Heart Failure; Humans; Male; SARS-CoV-2; Simendan; Systemic Inflammatory Response Syndrome	2022
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach. Current molecular pharmacology, 2023, Volume: 16, Issue:6 Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan	2023
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit. ESC heart failure, 2023, Volume: 10, Issue:1 Topics: Heart Failure; Humans; Intensive Care Units; Simendan; Stroke Volume; Ventricular Function, Left	2023
Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2023, Volume: 42, Issue:4 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Outpatients; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left	2023
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC heart failure, 2023, Volume: 10, Issue:2 Topics: Cardiotonic Agents; Cardiovascular Agents; Heart Failure; Humans; Registries; Retrospective Studies; Simendan; Treatment Outcome	2023
Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca ESC heart failure, 2023, Volume: 10, Issue:2 Topics: Animals; Dogs; Heart Failure; Myocytes, Cardiac; Myosins; Simendan; Stroke Volume	2023
A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation. Kardiologia polska, 2023, Volume: 81, Issue:3 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Inpatients; Poland; Pyridazines; Simendan	2023
[Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure]. Kardiologiia, 2023, Feb-28, Volume: 63, Issue:2 Topics: Cardiovascular Agents; Cross-Sectional Studies; Dobutamine; Heart Failure; Humans; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Function, Right	2023
Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2023, 05-02, Volume: 63, Issue:5 Topics: Adult; Heart Failure; Heart-Assist Devices; Humans; Propensity Score; Registries; Retrospective Studies; Simendan; Treatment Outcome	2023
Preoperative Levosimendan Administration in Heart Transplant Patients with Severe Hepatic and Renal Impairment: A Retrospective Study. The heart surgery forum, 2023, Aug-14, Volume: 26, Issue:4 Topics: Dobutamine; Dopamine; Heart Failure; Heart Transplantation; Humans; Renal Insufficiency; Retrospective Studies; Simendan	2023
Use of levosimendan in hemodynamic management of heart failure in two neonates with intracranial arteriovenous shunts: a case series. Italian journal of pediatrics, 2023, Oct-15, Volume: 49, Issue:1 Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Infant, Newborn; Pyridazines; Simendan	2023
Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry. ESC heart failure, 2023, Volume: 10, Issue:5 Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Registries; Risk Factors; Simendan; Stroke Volume; Ventricular Function, Left	2023
Intermittent levosimendan treatment for late onset right ventricular failure in a patient supported with a left ventricular assist device. Artificial organs, 2020, Volume: 44, Issue:5 Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Recovery of Function; Simendan; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right	2020
Old and New Drugs for Treatment of Advanced Heart Failure. Current pharmaceutical design, 2020, Volume: 26, Issue:14 Topics: Diuretics; Furosemide; Heart Failure; Humans; Prognosis; Simendan	2020
Effects of levosimendan on ventriculo-arterial coupling and cardiac efficiency in paediatric patients with single-ventricle physiology after surgical palliation: retrospective study. Interactive cardiovascular and thoracic surgery, 2020, 04-01, Volume: 30, Issue:4 Topics: Cardiac Output, Low; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hypoplastic Left Heart Syndrome; Infant; Infant, Newborn; Male; Retrospective Studies; Simendan; Stroke Volume; Univentricular Heart; Ventricular Function, Left	2020
Levosimendan – a valuable player in the treatment of a right-sided heart failure Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Aug-31, Volume: 72, Issue:8 Topics: Aged; Cardiotonic Agents; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2019
Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions. Minerva anestesiologica, 2020, Volume: 86, Issue:6 Topics: Critical Illness; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Shock, Cardiogenic; Simendan	2020
Levosimendan as bridge to transplant in patients with advanced heart failure. Revista espanola de cardiologia (English ed.), 2020, Volume: 73, Issue:5 Topics: Adult; Cardiotonic Agents; Heart Failure; Humans; Middle Aged; Simendan	2020
Ambulatory levosimendan infusions. Effective and efficient in advanced heart failure? Revista espanola de cardiologia (English ed.), 2020, Volume: 73, Issue:5 Topics: Cardiotonic Agents; Heart Failure; Humans; Infusions, Intravenous; Simendan; Treatment Outcome	2020
Successful Combination of Landiolol and Levosimendan in Patients with Decompensated Heart Failure. International heart journal, 2020, Mar-28, Volume: 61, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Morpholines; Simendan; Tachycardia; Urea	2020
Levosimendan with other inotropes or vasopressors: Should you combine them? The American journal of emergency medicine, 2020, Volume: 38, Issue:12 Topics: Acute Disease; Aged; Aged, 80 and over; Arterial Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospital Mortality; Humans; Hypotension; Length of Stay; Male; Middle Aged; Norepinephrine; Simendan; Tachycardia, Supraventricular; Treatment Outcome; Vasoconstrictor Agents	2020
Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with Levosimendan (Experimental Study). Bulletin of experimental biology and medicine, 2020, Volume: 169, Issue:1 Topics: Animals; Chronic Disease; Disease Models, Animal; Doxorubicin; Heart; Heart Failure; Heart Function Tests; Male; Myocardium; Rats; Rats, Wistar; Simendan	2020
Safety and efficacy of levosimendan in patients with cardiac amyloidosis. European journal of internal medicine, 2020, Volume: 80 Topics: Amyloidosis; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome	2020
Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiologia polska, 2020, 08-25, Volume: 78, Issue:7-8 Topics: Cardiotonic Agents; Expert Testimony; Heart Failure; Humans; Hydrazones; Poland; Pyridazines; Simendan	2020
COVID-19 infection in left ventricular assist device patients. Journal of cardiac surgery, 2020, Volume: 35, Issue:11 Topics: Aged; Cardiotonic Agents; COVID-19; Dobutamine; Furosemide; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Simendan; Ventricular Dysfunction, Right	2020
Repetitive levosimendan in outpatients affected by advanced heart failure: the need for a uniform approach. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 02-01, Volume: 22, Issue:2 Topics: Heart Failure; Humans; Hydrazones; Outpatients; Simendan	2021
Repeated infusion of levosimendan in outpatients with advanced heart failure: to cure sometimes, to relieve often, and to comfort always. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 02-01, Volume: 22, Issue:2 Topics: Heart Failure; Humans; Hydrazones; Outpatients; Simendan	2021
Effectiveness of Levosimendan in an 84-Year-Old Patient with Takotsubo Syndrome Complicated by Acute Heart Failure. The American journal of case reports, 2020, Oct-20, Volume: 21 Topics: Aged, 80 and over; Echocardiography; Heart Failure; Heart Ventricles; Humans; Male; Simendan; Takotsubo Cardiomyopathy	2020
Effects of Levosimendan on cardiac function, size and strain in heart failure patients. The international journal of cardiovascular imaging, 2021, Volume: 37, Issue:3 Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Recovery of Function; Retrospective Studies; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2021
Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2020, Volume: 29, Issue:11 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Poland; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left	2020
Levosimendan is safe to patients with advanced heart failure and hypotension. International journal of cardiology, 2021, 09-01, Volume: 338 Topics: Heart Failure; Humans; Hydrazones; Hypotension; Simendan	2021
Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial. Journal of cardiac failure, 2021, Volume: 27, Issue:9 Topics: Blood Volume; Heart Failure; Humans; Hypertension, Pulmonary; Simendan; Stroke Volume	2021
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered. Cardiology journal, 2021, Volume: 28, Issue:5 Topics: Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2021
Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension. Journal of cardiovascular pharmacology, 2017, Volume: 70, Issue:4 Topics: Animals; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Hydrazones; Hypertension, Pulmonary; Male; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Ventricular Dysfunction, Right	2017
High effectiveness of repeated levosimendan cycles in a patient with advanced heart failure. Medicina clinica, 2017, 09-08, Volume: 149, Issue:5 Topics: Aged; Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Humans; Simendan	2017
Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2017, Volume: 36, Issue:9 Topics: Acute Disease; Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Incidence; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan	2017
Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. The clinical respiratory journal, 2018, Volume: 12, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Cardiotonic Agents; China; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Injections, Intravenous; Middle Aged; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Receptors, Calcium-Sensing; Simendan; Survival Rate; Treatment Outcome; Ventricular Function, Right; Young Adult	2018
Levosimendan in Advanced Heart Failure: Where Do We Stand? Journal of cardiovascular pharmacology, 2018, Volume: 71, Issue:3 Topics: Heart Failure; Humans; Hydrazones; Simendan	2018
Hemodynamic support of a 15-year-old waiting for a heart transplant: Is there a role for levosimendan in pediatric heart failure? Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2018, Volume: 25, Issue:2 Topics: Adolescent; Cardiotonic Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Intensive Care Units, Pediatric; Male; Pyridazines; Simendan	2018
Repetitive levosimendan for a LION's heart? European journal of heart failure, 2018, Volume: 20, Issue:7 Topics: Administration, Intravenous; Ambulatory Care; Heart Failure; Humans; Outpatients; Simendan	2018
Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation. Pediatric cardiology, 2018, Volume: 39, Issue:7 Topics: Adolescent; Adult; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Infant; Infusions, Intravenous; Male; Milrinone; Retrospective Studies; Simendan; Survival Rate; Treatment Outcome; Young Adult	2018
Treatments targeting inotropy. European heart journal, 2019, 11-21, Volume: 40, Issue:44 Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholamines; Clinical Trials as Topic; Diastole; Dobutamine; Dogs; Energy Metabolism; Excitation Contraction Coupling; Heart Failure; Humans; Mitochondria; Models, Animal; Myocardial Contraction; Nitrogen Oxides; Oxidation-Reduction; Phosphodiesterase Inhibitors; Placebos; Receptors, Adrenergic; Sarcomeres; Shock, Cardiogenic; Simendan; Swine; Systole; Urea	2019
Does Levosimendan Have Room in Takotsubo Syndrome? JACC. Heart failure, 2019, Volume: 7, Issue:2 Topics: Heart Failure; Humans; Prognosis; Registries; Shock, Cardiogenic; Simendan; Takotsubo Cardiomyopathy	2019
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy. Pediatric cardiology, 2019, Volume: 40, Issue:3 Topics: Acute Disease; Adult; Cardiomyopathies; Cardiotonic Agents; Heart Failure; Humans; Lactic Acid; Male; Muscular Dystrophy, Duchenne; Natriuretic Peptide, Brain; Pneumonia; Simendan	2019
The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP. European review for medical and pharmacological sciences, 2019, Volume: 23, Issue:9 Topics: Acute Disease; Aged; Aged, 80 and over; Calcium; Cardiotonic Agents; Female; Heart Failure; Humans; Hypokalemia; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Potassium; Simendan; Stroke Volume; Ventricular Function, Left	2019
Optimization with levosimendan improves outcomes after left ventricular assist device implantation. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2020, 01-01, Volume: 57, Issue:1 Topics: Adult; Heart Failure; Heart-Assist Devices; Hemodynamics; Humans; Simendan; Thoracic Surgical Procedures; Treatment Outcome	2020
[Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report]. Kardiologia polska, 2013, Volume: 71, Issue:3 Topics: Adult; Aged; Cardiac Output, Low; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan	2013
Heart failure. Tardy but intact--publication of REVIVE trial results welcomed. Nature reviews. Cardiology, 2013, Volume: 10, Issue:6 Topics: Access to Information; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Information Dissemination; Pyridazines; Research Design; Simendan; Treatment Outcome	2013
Inhaled iloprost plus levosimendan to decompensate right heart failure due to chronic thromboembolic pulmonary hypertension. Anaesthesia and intensive care, 2013, Volume: 41, Issue:4 Topics: Administration, Inhalation; Critical Care; Diuretics; Furosemide; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Pyridazines; Simendan; Thromboembolism; Vasodilator Agents; Ventricular Dysfunction, Right	2013
Enteroviral myocarditis requiring extracorporeal membranous oxygenation in a 2 week old girl. The Israel Medical Association journal : IMAJ, 2013, Volume: 15, Issue:6 Topics: Cardiopulmonary Resuscitation; Cardiotonic Agents; Echocardiography; Enterovirus B, Human; Enterovirus Infections; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant, Newborn; Myocarditis; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left	2013
Levosimendan: a retrospective single-center case series. Journal of critical care, 2013, Volume: 28, Issue:6 Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Intensive Care Units; Male; Milrinone; Norepinephrine; Pyridazines; Retrospective Studies; Simendan; Sympathomimetics; Treatment Outcome	2013
eComment. Preoperative levosimendan administration in cardiac surgery patients. Interactive cardiovascular and thoracic surgery, 2013, Volume: 17, Issue:4 Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2013
eComment. Levosimendan in adult patients undergoing cardiac surgery. Interactive cardiovascular and thoracic surgery, 2013, Volume: 17, Issue:4 Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2013
eComment. Consider trying levosimendan. Interactive cardiovascular and thoracic surgery, 2013, Volume: 17, Issue:4 Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2013
Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene. Journal of applied physiology (Bethesda, Md. : 1985), 2013, Volume: 115, Issue:10 Topics: Animals; Calcium Signaling; Cardiotonic Agents; Diastole; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Heart Failure; Hydrazones; Hypertrophy, Left Ventricular; Mice; Mice, Knockout; Myocytes, Cardiac; Pyridazines; Recovery of Function; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Stroke Volume; Systole; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure	2013
Preconditioning with levosimendan before implantation of left ventricular assist devices. Artificial organs, 2014, Volume: 38, Issue:3 Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Female; Heart Failure; Heart-Assist Devices; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome	2014
Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure. Journal of cardiology, 2014, Volume: 63, Issue:6 Topics: Acute Disease; Aged; Cardiotonic Agents; Disease Progression; Dobutamine; Female; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Pyridazines; Retrospective Studies; Simendan	2014
Drug discovery and development for acute heart failure drugs: are expectations too high? International journal of cardiology, 2014, Mar-01, Volume: 172, Issue:1 Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Discovery; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Urea	2014
Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure. Acta physiologica (Oxford, England), 2014, Volume: 210, Issue:4 Topics: Animals; Calcium; Cardiotonic Agents; Female; Heart Failure; Hydrazones; Myocardial Infarction; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan	2014
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. British journal of pharmacology, 2014, Volume: 171, Issue:23 Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines	2014
Better late than never: a welcome publication of tardy clinical trial results. JACC. Heart failure, 2013, Volume: 1, Issue:2 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2013
Dead letter office. JACC. Heart failure, 2013, Volume: 1, Issue:2 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2013
Levosimendan in end-stage heart failure. JACC. Heart failure, 2013, Volume: 1, Issue:4 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2013
DUCCS and SWANS: when U.S. site-based research was highly successful. JACC. Heart failure, 2013, Volume: 1, Issue:4 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2013
Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation. Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:15-16 Topics: Cardiotonic Agents; Heart Failure; Heart Transplantation; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Right	2014
Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure. Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:4 Topics: Aged; Cardiac Catheterization; Cardiography, Impedance; Cardiotonic Agents; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Neurotransmitter Agents; Prognosis; Pyridazines; Simendan	2014
[Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2014, Volume: 109, Issue:4 Topics: Adult; Aged; Cardiac Output, Low; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Indocyanine Green; Infusions, Intravenous; Liver; Liver Failure; Liver Function Tests; Male; Middle Aged; Pilot Projects; Pyridazines; Regional Blood Flow; Simendan	2014
Preoperative levosimendan for right ventricular dysfunction before heart valve replacement surgery. Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:12 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Infusions, Intravenous; Male; Postoperative Complications; Preoperative Care; Pyridazines; Risk Assessment; Simendan; Spain; Treatment Outcome; Ventricular Dysfunction, Right	2013
Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. International journal of cardiology, 2014, Jun-15, Volume: 174, Issue:2 Topics: Chronic Disease; Heart Failure; Humans; Hydrazones; Practice Guidelines as Topic; Pyridazines; Severity of Illness Index; Simendan; Vasodilator Agents	2014
Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. International journal of cardiology, 2014, Jul-15, Volume: 175, Issue:1 Topics: Aged; Aged, 80 and over; Cardiology; Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Humans; Hydrazones; Internal Medicine; Male; Middle Aged; Pyridazines; Registries; Simendan; Survival Rate; Sweden	2014
Inotropic agents in advanced heart failure: repetita iuvant? International journal of cardiology, 2014, Volume: 176, Issue:1 Topics: Cardiotonic Agents; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Pyridazines; Severity of Illness Index; Simendan	2014
Early levosimendan administration may improve outcome in patients with subarachnoid hemorrhage complicated by acute heart failure. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Acute Disease; Adult; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Myocardial Contraction; Pyridazines; Simendan; Subarachnoid Hemorrhage; Time Factors	2014
Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure. American journal of physiology. Heart and circulatory physiology, 2014, Dec-01, Volume: 307, Issue:11 Topics: Animals; Arterio-Arterial Fistula; Calcium Signaling; Cardiotonic Agents; Heart Failure; Hydrazones; Male; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Pyridazines; Rats; Rats, Sprague-Dawley; Sarcomeres; Simendan; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left	2014
Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thrombosis and haemostasis, 2015, Volume: 113, Issue:2 Topics: Anti-Inflammatory Agents; Cell Adhesion; Cells, Cultured; Decanoic Acids; E-Selectin; Enzyme-Linked Immunosorbent Assay; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Hydrazones; Hydroxy Acids; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Interleukin-8; Microcirculation; Microscopy, Fluorescence; Muscle Cells; Myocardial Infarction; Myocytes, Cardiac; Necrosis; Neutrophils; NF-kappa B; Phosphorylation; Pyridazines; Reactive Oxygen Species; Simendan; Vasodilator Agents	2015
Experience with levosimendan in 32 paediatric patients. Pediatric cardiology, 2015, Volume: 36, Issue:5 Topics: Adolescent; Age Factors; Blood Pressure; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Male; Pyridazines; Retrospective Studies; Sex Factors; Simendan; Time Factors; Treatment Outcome	2015
Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:10 Topics: Biomarkers; Cardiotonic Agents; Cystatin C; Female; Heart Failure; Humans; Hydrazones; Kidney; Male; Pyridazines; Renal Insufficiency; Simendan	2017
Effects of levosimendan on heart failure in normotensive patients: does loading dose matter? Acute cardiac care, 2015, Volume: 17, Issue:1 Topics: Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Ultrasonography; Vasodilator Agents	2015
Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure. Scientific reports, 2015, Apr-13, Volume: 5 Topics: Anti-Inflammatory Agents; Biomarkers; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Female; Heart Failure; Humans; Hydrazones; Inflammation; Leukocytes; Male; Middle Aged; Neutrophils; Nitric Oxide; Peroxidase; Pyridazines; Severity of Illness Index; Simendan; Time Factors	2015
Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'. International journal of cardiology, 2015, Sep-15, Volume: 195 Topics: Adult; Cardiac Surgical Procedures; Cardiotonic Agents; Disease Progression; Female; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Life Expectancy; Male; Middle Aged; Postoperative Complications; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome	2015
Pharmaco-economics of levosimendan in cardiology: a European perspective. International journal of cardiology, 2015, Nov-15, Volume: 199 Topics: Acute Disease; Algorithms; Cardiology; Cardiotonic Agents; Cost-Benefit Analysis; Economics, Pharmaceutical; Europe; Heart Failure; Hospitalization; Humans; Hydrazones; Length of Stay; Models, Economic; Mortality; Pyridazines; Quality of Life; Simendan	2015
[Levosimendan-induced liver damage in an elderly patient with heart failure]. Zhonghua xin xue guan bing za zhi, 2015, Volume: 43, Issue:5 Topics: Aged; Chemical and Drug Induced Liver Injury; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2015
Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure. Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:4 Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Heart Failure; Hydrazones; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Myocardial Contraction; Pyridazines; Rats; Rats, Wistar; Simendan; Ventricular Dysfunction, Right; Ventricular Function, Right	2016
Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog. Journal of molecular and cellular cardiology, 2016, Volume: 92 Topics: Animals; Calcium; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Protein Conformation; Pyridazines; Rats; Simendan; Troponin C; Troponin I	2016
Levosimendan. A promising future drug for refractory cardiac failure in children? Indian heart journal, 2016, Volume: 68 Suppl 1 Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocarditis; Pyridazines; Simendan	2016
Levosimendan for Heart Failure. Journal of cardiothoracic and vascular anesthesia, 2016, Volume: 30, Issue:4 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2016
Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure. Acta cardiologica, 2016, Volume: 71, Issue:4 Topics: Aged; Biological Availability; Cardiotonic Agents; Disease Progression; Echocardiography, Doppler; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right	2016
Intermittent levosimendan infusions in advanced heart failure: a real world experience. The Journal of international medical research, 2017, Volume: 45, Issue:1 Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Function, Left	2017
Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure. Journal of cardiac failure, 2008, Volume: 14, Issue:5 Topics: Adrenergic beta-Agonists; Brachial Artery; Cardiotonic Agents; Case-Control Studies; Chronic Disease; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Myocardial Reperfusion; Oxygen Consumption; Prognosis; Prospective Studies; Pyridazines; Simendan; Spectroscopy, Near-Infrared; Vasodilator Agents	2008
Perioperative cardiac evaluation: the importance of cardiac failure management. Southern medical journal, 2008, Volume: 101, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Hydrazones; Myocardial Ischemia; Postoperative Complications; Pyridazines; Simendan	2008
BELIEF: believe it or not. Arquivos brasileiros de cardiologia, 2008, Volume: 91, Issue:2 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2008
Levosimendan in patients with decompensated heart failure. Arquivos brasileiros de cardiologia, 2008, Volume: 91, Issue:2 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2008
The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute cardiac care, 2008, Volume: 10, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Catecholamines; Female; Finland; Heart Failure; Hospital Mortality; Humans; Hydrazones; Length of Stay; Male; Middle Aged; Pyridazines; Retrospective Studies; Risk Factors; Simendan; Statistics, Nonparametric; Treatment Outcome	2008
Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure. The American journal of cardiology, 2008, Nov-01, Volume: 102, Issue:9 Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Stress; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume	2008
Tricuspid valve replacement and levosimendan. General thoracic and cardiovascular surgery, 2008, Volume: 56, Issue:11 Topics: Adult; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Diastole; Female; Follow-Up Studies; Heart Failure; Heart Rate; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Pyridazines; Simendan; Systole; Time Factors; Treatment Outcome; Tricuspid Valve; Vasodilator Agents	2008
Levosimendan: from basic science to clinical practice. Heart failure reviews, 2009, Volume: 14, Issue:4 Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Kidney; Myocardial Contraction; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Quality of Life; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right	2009
Rescuing a failing heart: putting on the squeeze. Nature medicine, 2009, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Middle Aged; Models, Biological; Myocardial Contraction; Pyridazines; Salvage Therapy; Simendan; Survival Analysis	2009
Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:2 Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Survival Rate; Treatment Outcome	2009
Levosimendan in heart failure after surgical repair of cardiac rupture. Minerva cardioangiologica, 2009, Volume: 57, Issue:1 Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Heart Rupture; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome	2009
Do levosimendan have an adverse effect on platelet function? International journal of cardiology, 2010, Oct-29, Volume: 144, Issue:3 Topics: Acute Disease; Blood Platelets; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Meta-Analysis as Topic; Platelet Aggregation; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2010
Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2009, Volume: 28, Issue:5 Topics: Adult; Aged; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Echocardiography, Transesophageal; Female; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Pyridazines; Simendan; Ventricular Dysfunction, Left	2009
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. Journal of the American College of Cardiology, 2009, Jun-23, Volume: 53, Issue:25 Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan	2009
Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009, Volume: 36, Issue:6 Topics: Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Case-Control Studies; Drug Administration Schedule; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Phosphodiesterase Inhibitors; Preanesthetic Medication; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left	2009
Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. Journal of hypertension, 2009, Volume: 27, Issue:10 Topics: Administration, Oral; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Failure; Homeodomain Proteins; Hydrazones; Male; Myocardial Infarction; Pyridazines; Rats; Rats, Mutant Strains; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; STAT1 Transcription Factor; Ventricular Remodeling	2009
Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Annals of emergency medicine, 2009, Volume: 54, Issue:6 Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Double-Blind Method; Drug Overdose; Heart Failure; Hemodynamics; Hydrazones; Propranolol; Pyridazines; Random Allocation; Simendan; Survival Analysis; Swine	2009
Levosimendan in viral myocarditis: not only an inodilator but also a cardioprotector? European journal of clinical investigation, 2009, Volume: 39, Issue:10 Topics: Heart Failure; Humans; Hydrazones; Myocarditis; Oxidative Stress; Pyridazines; Simendan; Vasodilator Agents	2009
Effects of levosimendan in experimental acute coxsackievirus myocarditis. European journal of clinical investigation, 2009, Volume: 39, Issue:10 Topics: Animals; Cardiotonic Agents; Coxsackievirus Infections; Heart Failure; Hydrazones; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Pyridazines; Simendan; Ventricular Function, Left	2009
Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function? Current drug targets, 2009, Volume: 10, Issue:9 Topics: Elective Surgical Procedures; Heart Failure; Humans; Hydrazones; Preoperative Care; Pyridazines; Risk Assessment; Simendan; Vasodilator Agents	2009
[Use of levosimendan in acute heart failure and its effect on renal function]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2009, Volume: 29, Issue:6 Topics: Acute Disease; Aged; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney; Male; Pyridazines; Simendan	2009
[Inotropic agents for treatment of acute heart failure syndromes in intensive care]. Revue medicale suisse, 2009, Dec-09, Volume: 5, Issue:229 Topics: Cardiotonic Agents; Critical Care; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2009
Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence? European journal of heart failure, 2010, Volume: 12, Issue:4 Topics: Acute Disease; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2010
In response to Leppikangas H, et al, Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Annals of emergency medicine, 2010, Volume: 55, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Hydrazones; Propranolol; Pyridazines; Simendan; Swine	2010
Rotating inotrope therapy in a pediatric population with decompensated heart failure. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2011, Volume: 12, Issue:1 Topics: Adolescent; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Male; Milrinone; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome	2011
Levosimendan in cardiac failure after subarachnoid hemorrhage. The Journal of trauma, 2010, Volume: 68, Issue:5 Topics: Acute Disease; Adult; Cardiotonic Agents; Critical Care; Embolization, Therapeutic; Female; Heart Failure; Humans; Hydrazones; Italy; Myocardial Stunning; Off-Label Use; Patient Selection; Pyridazines; Radiography; Simendan; Stroke Volume; Subarachnoid Hemorrhage; Treatment Outcome; Ventricular Function, Left	2010
Levosimendan and pulmonary hypertension. Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:7 Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Pulmonary Artery; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function	2010
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Current heart failure reports, 2010, Volume: 7, Issue:3 Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea	2010
Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence? European journal of heart failure, 2010, Volume: 12, Issue:8 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2010
How to treat acute decompensated heart failure in the 'beta-blocker era'? European journal of heart failure, 2010, Volume: 12, Issue:8 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vasodilator Agents	2010
Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter? Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Volume: 10, Issue:4 Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Diastole; Echocardiography; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Stroke Volume	2010
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure. Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:10 Topics: Angiotensin II; Angiotensinogen; Animals; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Heart; Heart Failure; Heart Rate; Humans; Hydrazones; Hypertension; Major Histocompatibility Complex; Male; Pyridazines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Renin-Angiotensin System; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan	2010
Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure. British journal of pharmacology, 2011, Volume: 162, Issue:3 Topics: Animals; Anti-Arrhythmia Agents; Calcium; Diaphragm; Heart Failure; Humans; Hydrazones; Male; Muscle Contraction; Muscle Fibers, Skeletal; Muscle Weakness; Myosin Heavy Chains; Pyridazines; Rats; Rats, Wistar; Simendan	2011
[Acute early postpartum cardiac failure associated with dilated cardiomyopathy: successful treatment with intra-aortic balloon counter-pulsation and levosimendan]. Annales francaises d'anesthesie et de reanimation, 2010, Volume: 29, Issue:11 Topics: Adult; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cesarean Section; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Postpartum Period; Pregnancy; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left	2010
Levosimendan in the treatment of cardiogenic shock. Minerva cardioangiologica, 2010, Volume: 58, Issue:4 Topics: Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Pyridazines; Shock, Cardiogenic; Simendan	2010
Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure. International journal of cardiology, 2012, May-17, Volume: 157, Issue:1 Topics: Aged; Atrial Function, Left; Biomarkers; Chronic Disease; Dobutamine; Echocardiography; Echocardiography, Stress; Female; Forecasting; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Treatment Outcome	2012
[Treatment of heart failure patients with inotropic drugs: beyond traditional agents]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:10 Suppl 1 Topics: Adrenergic beta-1 Receptor Agonists; Cardiotonic Agents; Dobutamine; Guidelines as Topic; Heart Failure; Hydrazones; Meta-Analysis as Topic; Phosphodiesterase Inhibitors; Pyridazines; Retrospective Studies; Risk Assessment; Simendan	2010
Levosimendan restores the positive force-frequency relation in heart failure. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:2 Topics: Analysis of Variance; Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Dogs; Excitation Contraction Coupling; Heart Failure; Heart Rate; Hydrazones; Male; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume; Tachycardia; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure	2011
Management of acute cardiac failure by intracoronary administration of levosimendan. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Blood Pressure; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyridazines; Simendan; Vascular Resistance; Ventricular Function, Left	2011
Cost-effectiveness of levosimendan in patients with acute heart failure. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:4 Topics: Acute Disease; Aged; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Patient Readmission; Pyridazines; Retrospective Studies; Simendan; Survival Rate	2011
Effects of levosimendan on cardiac gene expression profile and post-infarct cardiac remodelling in diabetic Goto-Kakizaki rats. Basic & clinical pharmacology & toxicology, 2011, Volume: 109, Issue:5 Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Gene Expression Profiling; Heart; Heart Failure; Hydrazones; Immunohistochemistry; Microarray Analysis; Myocardial Infarction; Myocardium; Pyridazines; Rats; Rats, Wistar; Renin-Angiotensin System; Simendan; Transcriptome; Up-Regulation; Ventricular Remodeling	2011
Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacological research, 2011, Volume: 64, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Cardiotonic Agents; Child; Digoxin; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan	2011
Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension. Pediatric cardiology, 2011, Volume: 32, Issue:7 Topics: Acute Disease; Adolescent; Cardiomyopathy, Dilated; Cardiotonic Agents; Diuresis; Dose-Response Relationship, Drug; Echocardiography, Doppler, Pulsed; Follow-Up Studies; Glycogen Storage Disease Type I; Heart Failure; Humans; Hydrazones; Hypertension; Infusions, Intravenous; Kidney Failure, Chronic; Male; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume	2011
Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Critical care (London, England), 2011, Jul-12, Volume: 15, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Austria; Cardiotonic Agents; Female; Flow Cytometry; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Male; Middle Aged; Neutrophils; Prospective Studies; Pyridazines; Reactive Oxygen Species; Shock, Septic; Simendan	2011
Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2011, Volume: 11, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Cohort Studies; Female; Heart Failure; Humans; Hydrazones; Insulin-Like Growth Factor I; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ultrasonography	2011
In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting. Critical care (London, England), 2011, Aug-18, Volume: 15, Issue:4 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Neutrophils; Pyridazines; Reactive Oxygen Species; Shock, Septic; Simendan	2011
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011, Volume: 62, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling	2011
Levosimendan--an inoprotective drug or much ado about nothing? Critical care medicine, 2011, Volume: 39, Issue:10 Topics: Cardiotonic Agents; Coronary Artery Bypass; Female; Heart Failure; Heart Valve Diseases; Humans; Hydrazones; Male; Pyridazines; Simendan	2011
Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiology journal, 2011, Volume: 18, Issue:5 Topics: Aged; Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Diastole; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Italy; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Systole; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left	2011
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure. Artificial organs, 2011, Volume: 35, Issue:11 Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan	2011
Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension. Neonatology, 2012, Volume: 101, Issue:3 Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Infant, Newborn; Male; Myocardial Ischemia; Pyridazines; Simendan; Treatment Outcome	2012
Inotropic support in the NICU: ever more compounds in search of guidance? Commentary on J. Esch et al.: differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation (Neonatology 2012;101:192–200) and M.P. De Caroli Neonatology, 2012, Volume: 101, Issue:3 Topics: Animals; Cardiac Output; Cardiotonic Agents; Female; Fetal Hypoxia; Heart Failure; Humans; Hydrazones; Hypertension, Pulmonary; Male; Myocardial Ischemia; Oxygen; Pyridazines; Simendan; Swine	2012
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. Vojnosanitetski pregled, 2011, Volume: 68, Issue:11 Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; Hydrazones; Male; Milrinone; Pyridazines; Simendan	2011
A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2012, Volume: 41, Issue:6 Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Hydrazones; Mitochondria, Heart; Myocardial Contraction; Oxygen Consumption; Pyridazines; Simendan; Sus scrofa; Ventricular Function, Left	2012
Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency. Bulletin of experimental biology and medicine, 2011, Volume: 150, Issue:5 Topics: Acetyldigoxins; Adenosine; Adenosine Triphosphate; Animals; Apoptosis; Cardiotonic Agents; Constriction, Pathologic; Female; Heart; Heart Failure; Heart Ventricles; Hydrazones; Male; Milrinone; Myocardium; Myocytes, Cardiac; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridazines; Rabbits; Reperfusion; Simendan; Ventricular Function	2011
ST-segment elevation during levosimendan infusion. Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:7 Topics: Acute Coronary Syndrome; Cardiotonic Agents; Coronary Angiography; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Middle Aged; Pyridazines; Simendan	2012
Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia. Arquivos brasileiros de cardiologia, 2012, Volume: 99, Issue:1 Topics: Aged; Anemia; Cardiotonic Agents; Chi-Square Distribution; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Matrix Metalloproteinase 1; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha	2012
The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure. Acta cardiologica, 2012, Volume: 67, Issue:3 Topics: Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Echocardiography; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Pyridazines; Simendan; Statistics, Nonparametric; Systole; Treatment Outcome	2012
Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Case-Control Studies; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Pyridazines; Recovery of Function; Simendan; Treatment Outcome; Ventricular Function, Left	2013
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. European heart journal, 2013, Volume: 34, Issue:10 Topics: Acute Disease; Aged; Alkaline Phosphatase; Cardiotonic Agents; Cholestasis; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Liver Diseases; Liver Function Tests; Male; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Transaminases	2013
Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. Advances in therapy, 2012, Volume: 29, Issue:12 Topics: Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Retrospective Studies; Rome; Simendan; Treatment Outcome	2012
Positive inotropy for acute heart failure complicating myocardial infarction. European heart journal, 2002, Volume: 23, Issue:18 Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Evaluation; Heart Failure; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Left	2002
15th Annual Congress of the European Society of Intensive Care Medicine, 29 September-2 October 2002, Barcelona, Spain: clinical research to improve outcome. Critical care (London, England), 2003, Volume: 7, Issue:1 Topics: Acute Kidney Injury; Critical Care; Europe; Heart Failure; Humans; Hydrazones; Incidence; Intensive Care Units; Lung Volume Measurements; Outcome Assessment, Health Care; Phosphodiesterase Inhibitors; Positive-Pressure Respiration; Pyridazines; Renal Replacement Therapy; Sepsis; Simendan; Societies, Medical; Spain	2003
Advances in positive inotropic therapy: levosimendan. Critical care medicine, 2003, Volume: 31, Issue:9 Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Prognosis; Pyridazines; Simendan; Treatment Outcome	2003
Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 2 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Diastole; Dobutamine; Dopamine; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Greece; Heart Failure; Heart Ventricles; Hematocrit; Hemoglobins; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Potassium; Pyridazines; Severity of Illness Index; Simendan; Stimulation, Chemical; Survival Analysis; Systole; Treatment Outcome; Ventricular Dysfunction, Left	2003
The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scandinavian cardiovascular journal : SCJ, 2004, Volume: 38, Issue:2 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Finland; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Probability; Pyridazines; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Simendan; Treatment Outcome	2004
Medical therapy in heart failure--is polypharmacy necessary? Annals of the Academy of Medicine, Singapore, 2004, Volume: 33, Issue:4 Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Mineralocorticoid Receptor Antagonists; Polypharmacy; Pyridazines; Simendan; Ventricular Function, Left	2004
Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node:. Pacing and clinical electrophysiology : PACE, 2004, Volume: 27, Issue:9 Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Bundle-Branch Block; Cardiotonic Agents; Catheter Ablation; Heart Block; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pacemaker, Artificial; Pyridazines; Simendan	2004
Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. Journal of cardiovascular pharmacology, 2004, Volume: 44, Issue:3 Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Carbon Isotopes; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Failure; Heart Rate; Hydrazones; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Myocardial Reperfusion; Myocardial Stunning; Oxygen Consumption; Perfusion; Phosphorus; Pyridazines; Simendan; Ventricular Function, Left	2004
Impact of levosimendan treatment on chronic heart failure. The American journal of cardiology, 2004, Oct-15, Volume: 94, Issue:8 Topics: Anti-Inflammatory Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2004
Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:2 Topics: Animals; Cardiotonic Agents; Diastole; Dogs; Heart Failure; Hydrazones; Pacemaker, Artificial; Physical Exertion; Pyridazines; Rest; Simendan; Systole; Ventricular Function, Left	2005
Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. The American journal of cardiology, 2005, Mar-15, Volume: 95, Issue:6 Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Pyridazines; Radionuclide Ventriculography; Risk; Simendan; Survival Rate	2005
Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. International journal of cardiology, 2005, Mar-30, Volume: 99, Issue:3 Topics: Aged; Cardiotonic Agents; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Pyridazines; Simendan	2005
Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia. The American journal of cardiology, 2005, Apr-01, Volume: 95, Issue:7 Topics: Anemia; Anti-Inflammatory Agents; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Weight Loss	2005
Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3 Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan	2005
[Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine]. Arquivos brasileiros de cardiologia, 2005, Volume: 85, Issue:1 Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Health Care Costs; Heart Failure; Hospital Costs; Humans; Hydrazones; Length of Stay; Pyridazines; Simendan	2005
What is the in vivo mechanism of action of levosimendan? Journal of cardiac failure, 2005, Volume: 11, Issue:6 Topics: Actins; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myosins; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Troponin C	2005
Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest, 2005, Volume: 128, Issue:4 Topics: Anti-Arrhythmia Agents; Blood Flow Velocity; Echocardiography, Doppler, Pulsed; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Regression Analysis; Simendan; Stroke Volume; Ventricular Function, Left	2005
Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:6 Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Ventricular Function, Left	2005
Resuscitation from adrenaline resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy. Resuscitation, 2006, Volume: 68, Issue:1 Topics: Adult; Cardiomyopathy, Dilated; Cardiopulmonary Resuscitation; Cardiotonic Agents; Epinephrine; Heart Arrest; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2006
Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long? European journal of heart failure, 2006, Volume: 8, Issue:2 Topics: C-Reactive Protein; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors; Treatment Outcome	2006
Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction. Heart, lung & circulation, 2006, Volume: 15, Issue:1 Topics: Aged; Aortic Valve Stenosis; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Left	2006
Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure? European journal of heart failure, 2006, Volume: 8, Issue:2 Topics: Alprostadil; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents	2006
The 2005 Scientific Sessions of the American Heart Association (AHA). Heart failure monitor, 2006, Volume: 5, Issue:1 Topics: American Heart Association; Animals; Cardiotonic Agents; Heart Failure; Hematopoietic Stem Cell Transplantation; Home Care Services; Humans; Hydrazones; Monitoring, Physiologic; Myocardial Infarction; Pacemaker, Artificial; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; United States	2006
[Therapy of acute decompensated heart failure with levosimendan]. Medizinische Klinik (Munich, Germany : 1983), 2006, Mar-22, Volume: 101 Suppl 1 Topics: Adult; Aged; Calcium Channel Agonists; Cardiotonic Agents; Conscious Sedation; Critical Care; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Pyridazines; Shock, Cardiogenic; Simendan	2006
Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy, 2006, Volume: 26, Issue:8 Pt 2 Topics: Acute Disease; Atrial Natriuretic Factor; Diuretics; Guideline Adherence; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents	2006
Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Critical care medicine, 2006, Volume: 34, Issue:11 Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Heart Failure; Hydrazones; Hypertension, Pulmonary; Prospective Studies; Pulmonary Artery; Pulmonary Circulation; Pyridazines; Random Allocation; Simendan; Ventricular Dysfunction, Right	2006
Clinical significance of acute neurohormonal response after levosimendan treatment. The American journal of cardiology, 2006, Oct-15, Volume: 98, Issue:8 Topics: Aged; Cardiotonic Agents; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome	2006
Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity. International journal of cardiology, 2007, Jun-12, Volume: 118, Issue:3 Topics: Acute Disease; Adult; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan; Treatment Outcome	2007
Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure. The Annals of thoracic surgery, 2006, Volume: 82, Issue:5 Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Vessels; Heart Failure; Humans; Hydrazones; Infusions, Intra-Arterial; Male; Pericardiectomy; Pyridazines; Simendan	2006
Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2007, Volume: 8, Issue:1 Topics: Cardiac Output, Low; Cardiotonic Agents; Echocardiography; Follow-Up Studies; Gestational Age; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Infant, Premature, Diseases; Intensive Care Units, Pediatric; Male; Myocardial Stunning; Postoperative Complications; Pyridazines; Simendan; Time Factors; Transposition of Great Vessels; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left	2007
Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients. The American journal of cardiology, 2007, Jan-01, Volume: 99, Issue:1 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Patient Selection; Pyridazines; Randomized Controlled Trials as Topic; Simendan	2007
Levosimendan: perpetuum mobile? European heart journal, 2007, Volume: 28, Issue:4 Topics: Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan	2007
Peripartum cardiomyopathy: a new successful setting for levosimendan. International journal of cardiology, 2008, Jan-24, Volume: 123, Issue:3 Topics: Adult; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Postpartum Period; Pregnancy; Pyridazines; Risk Assessment; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Dysfunction, Left	2008
Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? British journal of pharmacology, 2007, Volume: 150, Issue:7 Topics: Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan	2007
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Critical care medicine, 2007, Volume: 35, Issue:5 Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones; Lipopolysaccharides; Milrinone; Pyridazines; Rabbits; Sepsis; Simendan; Systole; Ventricular Function, Left	2007
Levosimendan: a new option in acute septic cardiac failure? Emergency medicine Australasia : EMA, 2007, Volume: 19, Issue:2 Topics: Acute Disease; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Sepsis; Simendan	2007
Patients with advanced heart failure and the effects of levosimendan. The American journal of cardiology, 2007, Aug-15, Volume: 100, Issue:4 Topics: Animals; Cardiotonic Agents; Echocardiography, Doppler; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right	2007
A struggle to SURVIVE: to abandon or not to abandon levosimendan? Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:5 Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome	2007
Is there a place for levosimendan in the intensive care unit? Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2007, Volume: 9, Issue:3 Topics: Cardiotonic Agents; Critical Care; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Intensive Care Units; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Failure	2007
Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. Clinical toxicology (Philadelphia, Pa.), 2008, Volume: 46, Issue:1 Topics: Animals; Antidotes; Blood Pressure; Calcium Chloride; Cardiac Output; Disease Models, Animal; Heart Failure; Heart Rate; Hydrazones; KATP Channels; Male; Poisoning; Pyridazines; Rats; Rats, Wistar; Simendan; Survival Rate; Vasodilator Agents; Verapamil	2008
Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al." Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:6 Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Pyridazines; Simendan	2007
Is there a place for levosimendan in the intensive care unit? Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2007, Volume: 9, Issue:4 Topics: Cardiotonic Agents; Critical Care; Heart Failure; Humans; Hydrazones; Intensive Care Units; Pyridazines; Simendan	2007
Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 325, Issue:1 Topics: Administration, Oral; Animals; Cardiotonic Agents; Diastole; Dogs; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Vasodilation; Ventricular Function, Left	2008
Levosimendan and ventriculo-arterial coupling. Acta anaesthesiologica Scandinavica, 2008, Volume: 52, Issue:3 Topics: Cardiac Output; Cardiotonic Agents; Doppler Effect; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vascular Resistance; Ventricular Dysfunction, Left	2008
Therapies for heart failure: a report from the Heart Failure Congress 2007. Timely topics in medicine. Cardiovascular diseases, 2007, Jul-13, Volume: 11 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Genetic Therapy; Heart Failure; Heart Transplantation; Hormone Replacement Therapy; Humans; Hydrazones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Mineralocorticoid Receptor Antagonists; Pyridazines; Simendan	2007
Can we believe in levosimendan? Arquivos brasileiros de cardiologia, 2008, Volume: 90, Issue:3 Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Simendan	2008
Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair. European journal of anaesthesiology, 2008, Volume: 25, Issue:8 Topics: Aged; Aged, 80 and over; Cardiac Output, Low; Cardiotonic Agents; Emergencies; Female; Heart Failure; Hemodynamics; Hip Fractures; Humans; Hydrazones; Infusions, Intravenous; Male; Natriuretic Peptides; Patient Selection; Preoperative Care; Pyridazines; Simendan; Survival Rate; Time Factors; Treatment Outcome; Troponin	2008
Preoperative levosimendan in heart failure patients undergoing noncardiac surgery. The Netherlands journal of medicine, 2008, Volume: 66, Issue:4 Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Elective Surgical Procedures; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Preoperative Care; Prospective Studies; Pyridazines; Risk Assessment; Simendan; Ultrasonography	2008
[Is there a role for levosimendan in hospital emergency departments?]. Revista espanola de cardiologia, 2008, Volume: 61, Issue:5 Topics: Acute Disease; Cardiotonic Agents; Emergency Service, Hospital; Emergency Treatment; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan	2008
Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach. International journal of cardiology, 2008, Aug-01, Volume: 128, Issue:1 Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors	2008
The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications. International journal of cardiology, 2008, Aug-01, Volume: 128, Issue:1 Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors	2008
Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. British journal of pharmacology, 1995, Volume: 114, Issue:3 Topics: Analysis of Variance; Animals; Aorta; Cardiac Pacing, Artificial; Cardiotonic Agents; Disease Models, Animal; Dogs; Electrodes, Implanted; Female; Heart Failure; Hemodynamics; Hydrazones; Male; Muscle Contraction; Muscle, Smooth, Vascular; Pyridazines; Simendan; Ventricular Function, Left	1995
Safety of levosimendan and other calcium sensitizers. Journal of cardiovascular pharmacology, 1995, Volume: 26 Suppl 1 Topics: Cardiotonic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Electrocardiography, Ambulatory; Heart Failure; Humans; Hydrazones; Male; Phosphodiesterase Inhibitors; Placebos; Pyridazines; Randomized Controlled Trials as Topic; Simendan	1995
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 1998, Nov-17, Volume: 98, Issue:20 Topics: Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Simendan	1998
[Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:2 Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Severity of Illness Index; Simendan	2001
Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. American journal of physiology. Heart and circulatory physiology, 2002, Volume: 282, Issue:1 Topics: Calcium; Cardiotonic Agents; Cyclic AMP; Fluorescent Dyes; Fura-2; Heart; Heart Failure; Heart Transplantation; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Muscle Fibers, Skeletal; Muscle Relaxation; Myocardial Contraction; Pyridazines; Reference Values; Simendan; Systole; Ventricular Function, Left	2002
[Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Duodecim; laaketieteellinen aikakauskirja, 2000, Volume: 116, Issue:20 Topics: Animals; Calcium; Cardiac Output, Low; Cardiotonic Agents; Clinical Trials as Topic; Heart; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Ventricular Function, Left	2000